Thomas Lee Ortel
Chief, Division of Hematology in the Department of Medicine
My research program investigates the molecular mechanisms whereby various congenital and acquired abnormalities result in ‘dysfunctional’ hemostasis (i.e., hemorrhage or thrombosis) to better understand the molecular mechanisms and interactions that are necessary for normal hemostasis. We are particularly interested in the mechanisms whereby antibodies and other inhibitors can interfere with normal hemostatic mechanisms. Several projects extensively overlap and focus on the assembly and function of procoagulant (e.g., factor X-ase and prothrombinase) and anticoagulant (e.g., activated protein C complex) phospholipid membrane-dependent complexes.
We utilize a variety of approaches in these studies. Monoclonal antibodies, single-chain variable domain fragments, polyclonal antibodies prepared from patients with factor VIII inhibitors, and site-specific mutagenesis have all been used to characterize structure-function relationships in coagulation factor VIII. Our laboratory has also extensively characterized anti-factor V antibodies, investigating autoantibodies as well as xenogenic antibodies developing after exposure to topical bovine thrombin preparations which contain trace amounts of contaminating bovine factor V. We have also characterized how antiphospholipid antibodies interfere with the activated protein C complex, a lipid-dependent natural anticoagulant complex that proteolytically inactivates factor Va and factor VIIIa.
Our current studies are focusing on two antibody-mediated thrombotic syndromes, heparin-induced thrombocytopenia and antiphospholipid antibody syndrome. First, we are initiating a large clinical trial investigating the incidence of clinically-significant heparin-induced thrombocytopenia in patients who develop anti-heparin/platelet factor 4 antibodies following cardiac bypass procedures. While these antibodies are commonly seen following cardiac bypass, the true incidence of thromboembolic complications related to these prothrombotic antibodies remains unknown. We are also collaborating with investigators in the Center for Human Genetics on a large, multi-center study exploring the genetics of familial antiphospholipid antibody syndrome. In addition, we have used a genomic strategy to investigate patients with antiphospholipid antibody syndrome and have identified a gene expression profile that appears to be unique to patients with this syndrome in contrast to patients with venous thromboembolism who do not have these autoantibodies.
We also participate in a variety of collaborative research efforts, both with individual investigators as well as participating in multi-center clinical research studies. For example, we are one of seventeen centers participating in the NIH-supported Transfusion Medicine/Hemostasis Network, and we are currently conducting a trial through this network to define the optimal dose of platelets for patients needing platelet transfusions for hypoproliferative thrombocytopenia. We are also part of a multi-center registry of patients with thrombotic thrombocytopenic purpura, and we are one of eight centers in the Hemostasis and Thrombosis Center pilot program sponsored by the Centers for Disease Control and Prevention. Participation in these registries and networks provides us with access to the patient populations that we study in the research laboratory.
We utilize a variety of approaches in these studies. Monoclonal antibodies, single-chain variable domain fragments, polyclonal antibodies prepared from patients with factor VIII inhibitors, and site-specific mutagenesis have all been used to characterize structure-function relationships in coagulation factor VIII. Our laboratory has also extensively characterized anti-factor V antibodies, investigating autoantibodies as well as xenogenic antibodies developing after exposure to topical bovine thrombin preparations which contain trace amounts of contaminating bovine factor V. We have also characterized how antiphospholipid antibodies interfere with the activated protein C complex, a lipid-dependent natural anticoagulant complex that proteolytically inactivates factor Va and factor VIIIa.
Our current studies are focusing on two antibody-mediated thrombotic syndromes, heparin-induced thrombocytopenia and antiphospholipid antibody syndrome. First, we are initiating a large clinical trial investigating the incidence of clinically-significant heparin-induced thrombocytopenia in patients who develop anti-heparin/platelet factor 4 antibodies following cardiac bypass procedures. While these antibodies are commonly seen following cardiac bypass, the true incidence of thromboembolic complications related to these prothrombotic antibodies remains unknown. We are also collaborating with investigators in the Center for Human Genetics on a large, multi-center study exploring the genetics of familial antiphospholipid antibody syndrome. In addition, we have used a genomic strategy to investigate patients with antiphospholipid antibody syndrome and have identified a gene expression profile that appears to be unique to patients with this syndrome in contrast to patients with venous thromboembolism who do not have these autoantibodies.
We also participate in a variety of collaborative research efforts, both with individual investigators as well as participating in multi-center clinical research studies. For example, we are one of seventeen centers participating in the NIH-supported Transfusion Medicine/Hemostasis Network, and we are currently conducting a trial through this network to define the optimal dose of platelets for patients needing platelet transfusions for hypoproliferative thrombocytopenia. We are also part of a multi-center registry of patients with thrombotic thrombocytopenic purpura, and we are one of eight centers in the Hemostasis and Thrombosis Center pilot program sponsored by the Centers for Disease Control and Prevention. Participation in these registries and networks provides us with access to the patient populations that we study in the research laboratory.
Current Appointments & Affiliations
- Chief, Division of Hematology in the Department of Medicine, Medicine, Hematology, Medicine 2013
- Professor of Medicine, Medicine, Hematology, Medicine 2008
- Professor of Pathology, Pathology, Clinical Science Departments 2008
- Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2002
Contact Information
- 0563 Stead Bldg, Durham, NC 27710
- Duke Box 3422, Durham, NC 27710
-
ortel001@mc.duke.edu
(919) 684-5350
-
Duke Hematology
-
Hemostasis & Thrombosis Center
- Background
-
Education, Training, & Certifications
- Fellow in Hematology-Oncology, Medicineq, Duke University 1988 - 1991
- Medical Resident, Medicine, Duke University 1985 - 1988
- M.D., Indiana University at Indianapolis 1985
- Ph.D., Indiana University at Bloomington 1983
-
Previous Appointments & Affiliations
- Associate Professor of Medicine, Medicine, Hematology, Medicine 2003 - 2008
- Associate Professor of Pathology, Pathology, Clinical Science Departments 2004 - 2008
- Assistant Professor of Pathology, Pathology, Clinical Science Departments 1994 - 2004
- Associate Professor of Medicine, Medicine, Hematology, Medicine 1999 - 2003
- Assistant Professor of Medicine, Medicine, Medical Oncology, Medicine 1993 - 1998
- Associate in the Department of Medicine, Medicine, Clinical Science Departments 1991 - 1993
- Recognition
-
In the News
-
AUG 27, 2015 WebMD -
JUN 23, 2015 Duke Today
-
-
Awards & Honors
- Expertise
-
Global Scholarship
-
Research
-
- Research
-
Selected Grants
- TAK-755-2001 A Phase 2b, multicenter, randomized, double-blind study of safety and efficacy of TAK-755 (rADAMTS13) with minimal to no plasma exchange (PEX) in the treatment of immune-mediated thrombotic thrombocytopenic purpura (iTTP) awarded by Takeda Development Center Americas, Inc 2023 - 2026
- Integrated Training in Anesthesiology Research awarded by National Institutes of Health 1996 - 2026
- Hematology & Transfusion Medicine (T32) awarded by National Institutes of Health 1975 - 2026
- Neurocognition & Greater Maintenance of Sinus Rhythm in AF (NOGGIN AF) awarded by National Institutes of Health 2021 - 2026
- The Role of RBC Reactive Oxygen Species in Regulating Thrombotic Events During Aging awarded by National Institutes of Health 2021 - 2026
- Anthos ANT-008 awarded by Anthos Therapeutics, Inc 2022 - 2026
- Anthos ANT-007 awarded by Anthos Therapeutics, Inc 2022 - 2026
- IL APS Fresh vs Frozen Clinical Agreement awarded by Instrumentation Laboratory Company 2018 - 2024
- Phase II, of oral SKI-O-703 in Chronic Immune Thrombocytopenia (ITP) awarded by Oscotec, Inc. 2019 - 2024
- (Takeda cTTP-2) A Phase 3b, open-label, continuation study of prophylactic and on-demand treatment of cTTP with TAK-755 (rADAMTS-13, also known as BAX 930/SHP655) awarded by Takeda Development Center Americas, Inc 2022 - 2024
- Developing apheresis-specific outcomes to facilitate a multi-center study of therapeutic plasma exchange in heparin-induced thrombocytopenia awarded by Robert Wood Johnson Foundation 2020 - 2023
- ASP002 A Phase 2, multicenter, open-label extension study to evaluate the long-term safety and tolerability of rozanolixizumab in adult study participants with primary antiphospholipid syndrome. awarded by UCB Biopharma 2021 - 2023
- Phase 3, prospective, randomized, controlled study of prophylatic and on-demand treatment of cTTP with BAX930 (rADAMTS13) awarded by Takeda Development Center Americas, Inc 2019 - 2023
- CISA Consult 2022 Contributing Task 3 awarded by Centers for Disease Control and Prevention 2022 - 2023
- A Phase 2, Uncontrolled, Two-stage, Dose-escalations Cohort Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Clinical activity of OMS721 in Adults with Thrombotic Microangiopathies awarded by Omeros 2014 - 2023
- ThRombosis exelUsion STudy for STA - Liatest D-DiXL (TRUST) awarded by Diagnostica Stago 2018 - 2023
- Postdoctoral Training in Genomic Medicine Research awarded by National Institutes of Health 2017 - 2023
- Stago themO® CE marking according to IVDR of DDi M reagent awarded by Diagnostica Stago 2022 - 2023
- HITSOVA Danaporiod vs Argatroban Phase III open-label, randomized trial awarded by Aspen Global Incorporated 2019 - 2023
- A randomized Phase 2 study evaluating the efficacy, safety, pharmacokinetics, and pharmacodynamics of rozanolixizumab relative to placebo in participants with primary antiphospholipid syndrome. awarded by UCB Biopharma SPRL 2021 - 2022
- IL ASP Clinical Outcome Study Agreement awarded by Instrumentation Laboratory Company 2018 - 2022
- Obizur EU PASS. Prospective and retrospective, non-interventional study to evaluate the safety and effectiveness of Obizur in real-life practice. awarded by Baxalta, Inc. 2019 - 2022
- Follow-up Study for Patients who Completed Study ALX0681-C301 (Post-HERCULES) awarded by Ablynx 2016 - 2022
- Improving venous thromboembolism surveillance with natural language processing awarded by Association of University Centers on Disabilities 2020 - 2022
- Role of myeloid KLF2 in antiphospholipid antibody-mediated thrombosis awarded by Case Western Reserve University 2018 - 2022
- ACTIV IV COVID-19 Post-hospital Thrombosis Prevention Study awarded by Research Triangle Institute International 2020 - 2022
- Stago NeoPTimal 5 mL and 10 mL Multi-Site Precision Study awarded by Diagnostica Stago 2022
- POST-MARKETING non-interventional safety evaluation of obizur in the treatment of bleeding episodes for patients with acquired hemophilia A awarded by Baxalta, Inc. 2016 - 2022
- Stago STA® - NeoPTimal 5 and 10 mL Single Site Precision Study awarded by Diagnostica Stago 2022
- PBI - Determination of Reproducibility and Accuracy of CRYOcheck Factor VIII Deficient Plasma with VWF awarded by Precision BioLogic, Inc 2022
- Siemans/VWF - Hemosil and REAADS Study awarded by Siemens Healthcare Diagnostics 2019 - 2021
- Stago - STA-NeoPTimal 5ml and 10 ml Single Site Precision Study awarded by Diagnostica Stago 2020 - 2021
- Stago - STA-NeoPTimal 5ml and 10m: Multisite Precision Study awarded by Diagnostica Stago 2020 - 2021
- L000013105 Protocol for Reagent Reproducibility of Liquid Anti-Xa Assay with Apixaban Calibrators on ACL TOP Analyzers awarded by Instrumentation Laboratory Company 2020 - 2021
- Defining the role of therapeutic plasma exchange in heparin induced thrombocytopenia awarded by Hemophilia & Thrombosis Research Society 2017 - 2020
- Evaluation, analysis, and dissemination of population-based cancer-associated venous thromboembolism (VTE) data awarded by Association of University Centers on Disabilities 2018 - 2020
- Apixaban for the Secondary prevention of Thromboembolism: a prospective, randomized, outcome pilot study amount patients with AntiphosPholipid Syndrome (ASTRO-APS) awarded by Intermountain Healthcare 2019
- L0022511987 Rev 01 Hemosil, Liquid Anti-Xa Assay with Apixaban Calibrators and Controls Performance Evaluation and Fresh vs Frozen Stability Protocol on ACL. TOP 50 Family Series Analyzers awarded by Instrumentation Laboratory Company 2018 - 2019
- L0022511991 Rev 01 Liquid Anti-Xa Assay with Rivaroxaban Calibrators and Controls Performance Evaluation Protocol on ACL TOP awarded by Instrumentation Laboratory Company 2018 - 2019
- LOO22511932 Rev 01 Hemosil Direct Thrombin Inhibitor (DTI) Assay with Dabigatran Calibrators and Controls awarded by Instrumentation Laboratory Company 2018 - 2019
- A Whole Blood Collection from subjects clinicially diagnosed with PNH awarded by Discovery Life Sciences, Inc. 2015 - 2019
- Duke-UNC Clinical Hematology and Transfusion Research Career Development Program awarded by National Institutes of Health 2006 - 2019
- Warfarin versus Direct Oral Anticoagulants for Secondary Prevention of Recurent Venous Thromboembolism awarded by Patient Centered Outcomes Research Institute 2017 - 2019
- Development of Prognostic Platelet RNA Biomarkers To Tailor Antiplatelet Therapy awarded by National Institutes of Health 2013 - 2019
- Task Order 1 under Master Eval Agreement #17072705 awarded by Diagnostica Stago 2017 - 2018
- U.S. External Site Protocol for Evaluation of Precision Performances of STA-THROMBIN ON STA-SATELLITE awarded by Diagnostica Stago 2017 - 2018
- External Evaluation of Assay Applications on The Sysmex CS2500 and CS-5100 Analyzer (Wave C) awarded by Siemens Healthcare Diagnostics 2016 - 2018
- A Phase I/II Open-Label Safety and Dose-Finding Study of Adeno- Associated Virus (AAV) rh10-Mediated Gene Transfer of Human Factor IX in Adults With Moderate/Severe to Severe Hemophilia B awarded by Dimension Therapeutics, Inc. 2016 - 2018
- Improving Pain in Sickle Cell Patients With Targeted Antithrombotic Therapy awarded by National Institutes of Health 2014 - 2017
- Training Program in Inflammatory and Immunological Diseases awarded by National Institutes of Health 1980 - 2017
- STA - Coag Control ABN PLUS Precision Study awarded by Stago 2017
- Evaluation of an Automated Information Extraction Tool for Identification of Venous Thromboembolism in Electronic Health Records (EHRs) awarded by Association of American Medical Colleges 2016 - 2017
- Population-based Surveillance And Ourcomes of Venous Thromboembolism awarded by Centers for Disease Control and Prevention 2015 - 2017
- Anticoagulation Withdrawal in Antiphospholipid Syndrome awarded by National Institutes of Health 2014 - 2017
- BRIDGE CCC awarded by National Institutes of Health 2008 - 2017
- Siemens CS-2100i and CS-5100 New Generation Analyzers awarded by Siemens Healthcare Diagnostics 2015 - 2017
- Precision Performance of STA® -COAG CONTROL (N + ABN) PLUS ON STA -SATELLITE® awarded by Stago 2016
- ALXN1007-APS-201 An Open-label proof of concept Phase IIa trial of ALXN1007 for the treatment of non-criteria manifestations of Antiphospholipid Syndrome awarded by Alexion Pharmaceuticals, Inc. 2014 - 2016
- Field Study to evaluate the activity of a site specific of B-Domain Deleted (BDD) pegylated recombinant FVIII protein (BAY 94-9027) in plasma samples measured with both chromogenic and one stage assa awarded by Bayer Healthcare Pharmaceuticals Inc 2015 - 2016
- Public Health Surveillance of Bleeding awarded by Centers for Disease Control and Prevention 2011 - 2016
- Adherence to Venous Thromboembolism Prophylaxis Guidelines in Hospitalized Elders awarded by National Institutes of Health 2014 - 2016
- Promoting the Health of Individuals with Clotting Disorders awarded by Centers for Disease Control and Prevention 2013 - 2015
- Population-based Surveillance And Outcomes of Venous Thromboembolism awarded by Centers for Disease Control and Prevention 2012 - 2015
- 12091912 INR Project awarded by DSRV Inc 2013 - 2014
- Transfusion Medicine/Hemostasis Core Clinical Center awarded by National Institutes of Health 2007 - 2014
- Clinical Significance of protamine/heparin antibodies after CPB awarded by National Institutes of Health 2011 - 2014
- Responses of Myocardial Ischemia to Sertraline Treatment awarded by National Institutes of Health 2006 - 2013
- Thrombosis and Hemostasis Centers Research and Prevention Network awarded by Centers for Disease Control and Prevention 2002 - 2013
- Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin awarded by National Institutes of Health 2009 - 2012
- Molecular Biology Of Human Coagulation Factor V awarded by National Institutes of Health 1991 - 2012
- Rare Thrombotic Diseases Clinical Research Network awarded by National Institutes of Health 2004 - 2010
- Lung Injury Protection by Coagulation Blockade awarded by National Institutes of Health 2005 - 2010
- Pharmacologic Prevention of Arteriovenous Graft Thrombosis awarded by National Institutes of Health 2007 - 2009
- Biomarker Studies for Novel Anti-Cancer Agents awarded by National Institutes of Health 2003 - 2008
- Hormone replacement therapy and ischemic stroke severity awarded by National Institutes of Health 2001 - 2007
- Integrated Program for Persons with Hemostatic Disorders awarded by Centers for Disease Control 2001 - 2007
- Mentored Clinical Research Scholar Program awarded by National Institutes of Health 2002 - 2006
- Does NO mediate clinical anti-VEGF vascular effects awarded by National Institutes of Health 2003 - 2006
- Genetic Analysis of Hereditary Macrothrombocytopenias awarded by National Institutes of Health 2001 - 2004
- Same awarded by Department of Health and Human Services 1999 - 2004
-
External Relationships
- Dade Behring, Inc. (Siemens)
- Diagnostica Stago
- Instrumentation Laboratory
- The American Society of Hematology (ASH)
- Up To Date Inc/Wolters Kluwer Health
- Publications & Artistic Works
-
Selected Publications
-
Academic Articles
-
Wang, Tracy Y., Abdus S. Wahed, Alison Morris, Lisa Baumann Kreuziger, John G. Quigley, Gervasio A. Lamas, Alexandra J. Weissman, et al. “Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization.” Ann Intern Med 176, no. 4 (April 2023): 515–23. https://doi.org/10.7326/M22-3350.Full Text Link to Item
-
Friede, Kevin A., Rachel A. Myers, Jordan Gales, Ilya Zhbannikov, Thomas L. Ortel, Svati H. Shah, William E. Kraus, Geoffrey S. Ginsburg, and Deepak Voora. “An antiplatelet response gene expression signature is associated with bleeding.” Cardiovasc Res 119, no. 2 (March 31, 2023): 551–60. https://doi.org/10.1093/cvr/cvac079.Full Text Link to Item
-
Zuo, Yu, Sherwin Navaz, Alex Tsodikov, Katarina Kmetova, Lyndsay Kluge, Amala Ambati, Claire K. Hoy, et al. “Anti-Neutrophil Extracellular Trap Antibodies in Antiphospholipid Antibody-Positive Patients: Results From the Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking Clinical Database and Repository.” Arthritis Rheumatol, March 2, 2023. https://doi.org/10.1002/art.42489.Full Text Link to Item
-
Knight, Jason S., D Ware Branch, and Thomas L. Ortel. “Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management.” Bmj 380 (February 27, 2023): e069717. https://doi.org/10.1136/bmj-2021-069717.Full Text Link to Item
-
Chighizola, Cecilia B., Francesca Pregnolato, Danieli Andrade, Maria Tektonidou, Vittorio Pengo, Guillermo Ruiz-Irastorza, H Michael Belmont, et al. “Fluctuation of Anti-Domain 1 and Anti-β2 -Glycoprotein I Antibody Titers Over Time in Patients With Persistently Positive Antiphospholipid Antibodies.” Arthritis Rheumatol, January 27, 2023. https://doi.org/10.1002/art.42459.Full Text Link to Item
-
Wang, Tzu-Fei, Kristen M. Sanfilippo, James Douketis, Anna Falanga, John Karageorgiou, Anthony Maraveyas, Thomas L. Ortel, Gerald Soff, Suresh Vedantham, and Jeffrey I. Zwicker. “Peri-procedure management of antithrombotic agents and thrombocytopenia for common procedures in oncology: Guidance from the SSC of the ISTH.” J Thromb Haemost 20, no. 12 (December 2022): 3026–38. https://doi.org/10.1111/jth.15896.Full Text Link to Item
-
Saber, Ibrahim, Alys Adamski, Maragatha Kuchibhatla, Karon Abe, Michele Beckman, Nimia Reyes, Ryan Schulteis, et al. “Racial differences in venous thromboembolism: A surveillance program in Durham County, North Carolina.” Res Pract Thromb Haemost 6, no. 5 (July 2022): e12769. https://doi.org/10.1002/rth2.12769.Full Text Link to Item
-
Haykal, Tarek, Yazan Zayed, Josiane Kerbage, Smit Deliwala, Chandler A. Long, and Thomas L. Ortel. “Meta-analysis and systematic review of randomized controlled trials assessing the role of thromboprophylaxis after vascular surgery.” J Vasc Surg Venous Lymphat Disord 10, no. 3 (May 2022): 767-777.e3. https://doi.org/10.1016/j.jvsv.2021.08.019.Full Text Link to Item
-
Myers, Rachel A., Thomas L. Ortel, Alexander Waldrop, Sandeep Dave, Geoffrey S. Ginsburg, and Deepak Voora. “Aspirin effects on platelet gene expression are associated with a paradoxical, increase in platelet function.” British Journal of Clinical Pharmacology 88, no. 5 (May 2022): 2074–83. https://doi.org/10.1111/bcp.15127.Full Text
-
See, Isaac, Allison Lale, Paige Marquez, Michael B. Streiff, Allison P. Wheeler, Naomi K. Tepper, Emily Jane Woo, et al. “Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination-United States, December 2020 to August 2021.” Ann Intern Med 175, no. 4 (April 2022): 513–22. https://doi.org/10.7326/M21-4502.Full Text Link to Item
-
Wiercioch, Wojtek, Robby Nieuwlaat, Yuan Zhang, Pablo Alonso-Coello, Philipp Dahm, Alfonso Iorio, Veena Manja, et al. “New methods facilitated the process of prioritizing questions and health outcomes in guideline development.” J Clin Epidemiol 143 (March 2022): 91–104. https://doi.org/10.1016/j.jclinepi.2021.11.031.Full Text Link to Item
-
Vestal, Mark L., Kimberly Hodulik, Jennifer Mando-Vandrick, Michael L. James, Thomas L. Ortel, Matthew Fuller, Maria Notini, Mark Friedland, and Ian J. Welsby. “Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage.” J Thromb Thrombolysis 53, no. 1 (January 2022): 167–75. https://doi.org/10.1007/s11239-021-02495-3.Full Text Link to Item
-
Wahid, Lana, and Thomas L. Ortel. “Anticoagulant Therapy in Patients Hospitalized With COVID-19.” Jama Intern Med 181, no. 12 (December 1, 2021): 1621–22. https://doi.org/10.1001/jamainternmed.2021.6212.Full Text Open Access Copy Link to Item
-
Nieuwlaat, Robby, Wojtek Wiercioch, Jan L. Brozek, Nancy Santesso, Robert Kunkle, Pablo Alonso-Coello, David R. Anderson, et al. “How to write a guideline: a proposal for a manuscript template that supports the creation of trustworthy guidelines.” Blood Adv 5, no. 22 (November 23, 2021): 4721–26. https://doi.org/10.1182/bloodadvances.2020003577.Full Text Link to Item
-
Jindal, Ankur K., Jasmina Ahluwalia, Rajiv Suku, Deepti Suri, Karen Nuytemans, Thomas L. Ortel, Margaret A. Pericak-Vance, Jeffery M. Vance, and Surjit Singh. “Successful Management of Catastrophic Thrombotic Storm in a Young Boy: A Case Report From Northern India.” J Pediatr Hematol Oncol 43, no. 8 (November 1, 2021): e1132–35. https://doi.org/10.1097/MPH.0000000000002069.Full Text Link to Item
-
Streiff, Michael B., Bjorn Holmstrom, Dana Angelini, Aneel Ashrani, Amro Elshoury, John Fanikos, Kleber Yotsumoto Fertrin, et al. “Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 19, no. 10 (October 15, 2021): 1181–1201. https://doi.org/10.6004/jnccn.2021.0047.Full Text Link to Item
-
Barbhaiya, Medha, Stephane Zuily, Yasaman Ahmadzadeh, Mary-Carmen Amigo, Tadej Avcin, Maria Laura Bertolaccini, D Ware Branch, et al. “Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria.” Arthritis Care Res (Hoboken) 73, no. 10 (October 2021): 1490–1501. https://doi.org/10.1002/acr.24520.Full Text Link to Item
-
Wiercioch, Wojtek, Robby Nieuwlaat, Philipp Dahm, Alfonso Iorio, Reem A. Mustafa, Ignacio Neumann, Bram Rochwerg, et al. “Development and application of health outcome descriptors facilitated decision-making in the production of practice guidelines.” J Clin Epidemiol 138 (October 2021): 115–27. https://doi.org/10.1016/j.jclinepi.2021.04.016.Full Text Link to Item
-
Arepally, Gowthami M., and Thomas L. Ortel. “Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT): What We Know and Don't Know.” Blood, June 1, 2021. https://doi.org/10.1182/blood.2021012152.Full Text Link to Item
-
Haykal, Tarek, Soheir Adam, Areeg Bala, Yazan Zayed, Smit Deliwala, Josiane Kerbage, Anoosha Ponnapalli, Srikanth Malladi, Varun Samji, and Thomas L. Ortel. “Thromboprophylaxis for orthopedic surgery; An updated meta-analysis.” Thromb Res 199 (March 2021): 43–53. https://doi.org/10.1016/j.thromres.2020.12.007.Full Text Link to Item
-
Infeld, Margaret, Kevin A. Friede, Tan Ru San, Holly J. Knickerbocker, Geoffrey S. Ginsburg, Thomas L. Ortel, and Deepak Voora. “Platelet reactivity in response to aspirin and ticagrelor in African-Americans and European-Americans.” J Thromb Thrombolysis 51, no. 2 (February 2021): 249–59. https://doi.org/10.1007/s11239-020-02327-w.Full Text Link to Item
-
Ridker, Paul M., Thomas L. Ortel, and Judith S. Hochman. “Equipoise, Trust, and the Need for Cardiologists to Randomly Assign Patients Into Anticoagulation Trials in the Time of COVID.” Circulation 142, no. 24 (December 15, 2020): 2296–98. https://doi.org/10.1161/CIRCULATIONAHA.120.052069.Full Text Link to Item
-
Daughety, Molly M., Andrew Morgan, Erin Frost, Chester Kao, Joyce Hwang, Rachel Tobin, Bhavik Patel, Matthew Fuller, Ian Welsby, and Thomas L. Ortel. “COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy.” Thromb Res 196 (December 2020): 483–85. https://doi.org/10.1016/j.thromres.2020.10.004.Full Text Link to Item
-
Haykal, Tarek, Soheir Adam, and Thomas L. Ortel. “Meta-analysis fever in the wake of CARAVAGGIO.” Thromb Res 196 (December 2020): 141–42. https://doi.org/10.1016/j.thromres.2020.08.036.Full Text Link to Item
-
Devreese, Katrien M. J., Philip G. de Groot, Bas de Laat, Doruk Erkan, Emmanuel J. Favaloro, Ian Mackie, Marta Martinuzzo, et al. “Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation.” J Thromb Haemost 18, no. 11 (November 2020): 2828–39. https://doi.org/10.1111/jth.15047.Full Text Link to Item
-
Ortel, Thomas L., Ignacio Neumann, Walter Ageno, Rebecca Beyth, Nathan P. Clark, Adam Cuker, Barbara A. Hutten, et al. “American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism.” Blood Adv 4, no. 19 (October 13, 2020): 4693–4738. https://doi.org/10.1182/bloodadvances.2020001830.Full Text Link to Item
-
Cohen, Hannah, Maria J. Cuadrado, Doruk Erkan, Ali Duarte-Garcia, David A. Isenberg, Jason S. Knight, Thomas L. Ortel, et al. “16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends.” Lupus 29, no. 12 (October 2020): 1571–93. https://doi.org/10.1177/0961203320950461.Full Text Link to Item
-
Ortel, Thomas L., Sreelatha Meleth, Diane Catellier, Mark Crowther, Doruk Erkan, Paul R. Fortin, David Garcia, et al. “Recurrent thrombosis in patients with antiphospholipid antibodies and an initial venous or arterial thromboembolic event: A systematic review and meta-analysis.” J Thromb Haemost 18, no. 9 (September 2020): 2274–86. https://doi.org/10.1111/jth.14936.Full Text Link to Item
-
Thachil, Jecko, Nicole P. Juffermans, Marco Ranucci, Jean M. Connors, Theodore E. Warkentin, Thomas L. Ortel, Marcel Levi, Toshiaki Iba, and Jerrold H. Levy. “ISTH DIC subcommittee communication on anticoagulation in COVID-19.” J Thromb Haemost 18, no. 9 (September 2020): 2138–44. https://doi.org/10.1111/jth.15004.Full Text Link to Item
-
Sung, Anthony D., Richard C. Yen, Yiqun Jiao, Alyssa Bernanke, Deborah A. Lewis, Sara E. Miller, Zhiguo Li, et al. “Fibrinogen-Coated Albumin Nanospheres Prevent Thrombocytopenia-Related Bleeding.” Radiat Res 194, no. 2 (August 1, 2020): 162–72. https://doi.org/10.1667/RADE-20-00016.Full Text Link to Item
-
Zuily, Stéphane, Isabelle Clerc-Urmès, Cédric Bauman, Danieli Andrade, Savino Sciascia, Vittorio Pengo, Maria G. Tektonidou, et al. “Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry.” Lupus, July 23, 2020, 961203320940776. https://doi.org/10.1177/0961203320940776.Full Text Link to Item
-
Friede, Kevin A., Margaret M. Infeld, Ru San Tan, Holly J. Knickerbocker, Rachel A. Myers, Laura G. Dubois, J Will Thompson, et al. “Influence of Sex on Platelet Reactivity in Response to Aspirin.” J Am Heart Assoc 9, no. 14 (July 21, 2020): e014726. https://doi.org/10.1161/JAHA.119.014726.Full Text Link to Item
-
Root, A. G., R. D. Raiff, T. L. Ortel, and K. L. Hodulik. “Initiation of Emicizumab Therapy in an Adult Patient With Hemophilia A With Inhibitors and Associated Drug Cost Savings.” Journal of Pharmacy Technology 36, no. 3 (June 1, 2020): 110–13. https://doi.org/10.1177/8755122520906291.Full Text
-
Wiercioch, Wojtek, Robby Nieuwlaat, Elie A. Akl, Robert Kunkle, Kendall E. Alexander, Adam Cuker, Anita Rajasekhar, et al. “Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences.” Blood Adv 4, no. 10 (May 26, 2020): 2351–65. https://doi.org/10.1182/bloodadvances.2020001768.Full Text Link to Item
-
Pavon, Juliessa M., Richard J. Sloane, Carl F. Pieper, Cathleen S. Colón-Emeric, David Gallagher, Harvey J. Cohen, Katherine S. Hall, et al. “Physical Activity in the Hospital: Documentation and Influence on Venous Thromboembolism Prophylaxis.” J Aging Phys Act 28, no. 2 (April 24, 2020): 306–10. https://doi.org/10.1123/japa.2018-0462.Full Text Link to Item
-
Khatib, Rasha, Stephanie Ross, Sean Alexander Kennedy, Ivan D. Florez, Thomas L. Ortel, Robby Nieuwlaat, Ignacio Neumann, et al. “Home vs hospital treatment of low-risk venous thromboembolism: a systematic review and meta-analysis.” Blood Adv 4, no. 3 (February 11, 2020): 500–513. https://doi.org/10.1182/bloodadvances.2019001223.Full Text Link to Item
-
Ortel, Thomas L. “Introduction to a review series on treatment of venous thrombotic disorders.” Blood 135, no. 5 (January 30, 2020): 299–300. https://doi.org/10.1182/blood.2019004079.Full Text Link to Item
-
Hashmi, Nazish K., Kamrouz Ghadimi, Amudan J. Srinivasan, Yi-Ju Li, Robert D. Raiff, Jeffrey G. Gaca, Adam G. Root, et al. “Three-factor prothrombin complex concentrates for refractory bleeding after cardiovascular surgery within an algorithmic approach to haemostasis.” Vox Sang 114, no. 4 (May 2019): 374–85. https://doi.org/10.1111/vox.12774.Full Text Link to Item
-
Ortel, Thomas L., Katie Arnold, Michele Beckman, Audrey Brown, Nimia Reyes, Ibrahim Saber, Ryan Schulteis, Bhavana Pendurthi Singh, Andrea Sitlinger, and Elizabeth H. Thames. “Design and Implementation of a Comprehensive Surveillance System for Venous Thromboembolism in a Defined Region Using Electronic and Manual Approaches.” Appl Clin Inform 10, no. 3 (May 2019): 552–62. https://doi.org/10.1055/s-0039-1693711.Full Text Link to Item
-
Arepally, Gowthami M., and Thomas L. Ortel. “Bad weed: synthetic cannabinoid-associated coagulopathy.” Blood 133, no. 9 (February 28, 2019): 902–5. https://doi.org/10.1182/blood-2018-11-876839.Full Text Link to Item
-
Ortel, Thomas L. “Introduction to a review series on new therapeutics for inherited and acquired bleeding conditions.” Blood 133, no. 5 (January 31, 2019): 383–84. https://doi.org/10.1182/blood-2018-12-877779.Full Text Link to Item
-
Streiff, Michael B., Bjorn Holmstrom, Dana Angelini, Aneel Ashrani, Paula L. Bockenstedt, Carolyn Chesney, John Fanikos, et al. “NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018.” J Natl Compr Canc Netw 16, no. 11 (November 2018): 1289–1303. https://doi.org/10.6004/jnccn.2018.0084.Full Text Link to Item
-
Devreese, K. M. J., T. L. Ortel, V. Pengo, and B. de Laat. “Laboratory criteria for antiphospholipid syndrome: reply.” J Thromb Haemost 16, no. 10 (October 2018): 2117–19. https://doi.org/10.1111/jth.14238.Full Text Link to Item
-
Onwuemene, Oluwatoyosi A., Steven C. Grambow, Chetan B. Patel, Robert J. Mentz, Carmelo A. Milano, Joseph G. Rogers, Ara D. Metjian, Gowthami M. Arepally, and Thomas L. Ortel. “Indications for and outcomes of therapeutic plasma exchange after cardiac transplantation: A single center retrospective study.” J Clin Apher 33, no. 4 (August 2018): 469–79. https://doi.org/10.1002/jca.21622.Full Text Open Access Copy Link to Item
-
Castellucci, Lana A., Kerstin de Wit, David Garcia, Thomas L. Ortel, and Grégoire Le Gal. “Extended anticoagulation for unprovoked venous thromboembolism.” Res Pract Thromb Haemost 2, no. 3 (July 2018): 529–34. https://doi.org/10.1002/rth2.12121.Full Text Link to Item
-
Pavon, Juliessa M., Richard J. Sloane, Carl F. Pieper, Cathleen S. Colón-Emeric, Harvey J. Cohen, David Gallagher, Miriam C. Morey, Midori McCarty, Thomas L. Ortel, and Susan N. Hastings. “Automated versus Manual Data Extraction of the Padua Prediction Score for Venous Thromboembolism Risk in Hospitalized Older Adults.” Appl Clin Inform 9, no. 3 (July 2018): 743–51. https://doi.org/10.1055/s-0038-1670678.Full Text Link to Item
-
Pavon, Juliessa M., Richard J. Sloane, Carl F. Pieper, Cathleen S. Colón-Emeric, Harvey J. Cohen, David Gallagher, Miriam C. Morey, Midori McCarty, Thomas L. Ortel, and Susan N. Hastings. “Poor Adherence to Risk Stratification Guidelines Results in Overuse of Venous Thromboembolism Prophylaxis in Hospitalized Older Adults.” J Hosp Med 13, no. 6 (June 1, 2018): 403–4. https://doi.org/10.12788/jhm.2916.Full Text Open Access Copy Link to Item
-
Borst, Alexandra J., Debra L. Sudan, Laura A. Wang, Michael J. Neuss, Jennifer A. Rothman, and Thomas L. Ortel. “Bleeding and thrombotic complications of pediatric liver transplant.” Pediatr Blood Cancer 65, no. 5 (May 2018): e26955. https://doi.org/10.1002/pbc.26955.Full Text Link to Item
-
Devreese, K. M. J., T. L. Ortel, V. Pengo, B. de Laat, and B. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. “Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH.” J Thromb Haemost 16, no. 4 (April 2018): 809–13. https://doi.org/10.1111/jth.13976.Full Text Link to Item
-
Rabinovich, A., T. Ducruet, S. R. Kahn, and S. R. SOX Trial investigators. “Development of a clinical prediction model for the postthrombotic syndrome in a prospective cohort of patients with proximal deep vein thrombosis.” J Thromb Haemost 16, no. 2 (February 2018): 262–70. https://doi.org/10.1111/jth.13909.Full Text Link to Item
-
Nuytemans, Karen, Thomas L. Ortel, Lissette Gomez, Natalia Hofmann, Natalie Alves, Nicole Dueker, Ashley Beecham, et al. “Variants in chondroitin sulfate metabolism genes in thrombotic storm.” Thromb Res 161 (January 2018): 43–51. https://doi.org/10.1016/j.thromres.2017.11.016.Full Text Link to Item
-
Clark, Nathan P., James D. Douketis, Vic Hasselblad, Sam Schulman, Andrei L. Kindzelski, Thomas L. Ortel, and Thomas L. BRIDGE Investigators. “Predictors of perioperative major bleeding in patients who interrupt warfarin for an elective surgery or procedure: Analysis of the BRIDGE trial.” Am Heart J 195 (January 2018): 108–14. https://doi.org/10.1016/j.ahj.2017.09.015.Full Text Link to Item
-
Kuter, David J., Barbara A. Konkle, Taye H. Hamza, Lynne Uhl, Susan F. Assmann, Joseph E. Kiss, Richard M. Kaufman, et al. “Clinical outcomes in a cohort of patients with heparin-induced thrombocytopenia.” Am J Hematol 92, no. 8 (August 2017): 730–38. https://doi.org/10.1002/ajh.24759.Full Text Link to Item
-
Gibson, C Michael, Serge Korjian, Gerald Chi, Yazan Daaboul, Purva Jain, Douglas Arbetter, Samuel Z. Goldhaber, et al. “Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy.” J Am Heart Assoc 6, no. 7 (July 11, 2017). https://doi.org/10.1161/JAHA.117.006015.Full Text Link to Item
-
Arepally, Gowthami M. “Heparin-induced thrombocytopenia.” Blood 129, no. 21 (May 25, 2017): 2864–72. https://doi.org/10.1182/blood-2016-11-709873.Full Text Link to Item
-
Sun, Julia L., Stephen H. Boyle, Zainab Samad, Michael A. Babyak, Jennifer L. Wilson, Cynthia Kuhn, Richard C. Becker, et al. “Mental stress-induced left ventricular dysfunction and adverse outcome in ischemic heart disease patients.” Eur J Prev Cardiol 24, no. 6 (April 2017): 591–99. https://doi.org/10.1177/2047487316686435.Full Text Link to Item
-
Rodger, Marc A., Gregoire Le Gal, David R. Anderson, Jeannot Schmidt, Gilles Pernod, Susan R. Kahn, Marc Righini, et al. “Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study.” Bmj 356 (March 17, 2017): j1065. https://doi.org/10.1136/bmj.j1065.Full Text Link to Item
-
Doherty, John U., Ty J. Gluckman, William J. Hucker, James L. Januzzi, Thomas L. Ortel, Sherry J. Saxonhouse, and Sarah A. Spinler. “2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation: A Report of the American College of Cardiology Clinical Expert Consensus Document Task Force.” J Am Coll Cardiol 69, no. 7 (February 21, 2017): 871–98. https://doi.org/10.1016/j.jacc.2016.11.024.Full Text Link to Item
-
Feigal, Jacob P., Stephen H. Boyle, Zainab Samad, Eric J. Velazquez, Jennifer L. Wilson, Richard C. Becker, Redford B. Williams, et al. “Associations between positive emotional well-being and stress-induced myocardial ischemia: Well-being scores predict exercise-induced ischemia.” Journal of Psychosomatic Research 93 (February 2017): 14–18. https://doi.org/10.1016/j.jpsychores.2016.11.012.Full Text
-
Komforti, Miglena K., Elizabeth S. Bressler, Maria A. Selim, Garrett S. Bressler, and Thomas L. Ortel. “A rare cutaneous manifestation of hemorrhagic bullae to low-molecular-weight heparin and fondaparinux: report of two cases.” J Cutan Pathol 44, no. 1 (January 2017): 104–6. https://doi.org/10.1111/cup.12821.Full Text Link to Item
-
Welsby, I. J., E. F. Krakow, J. A. Heit, E. C. Williams, G. M. Arepally, S. Bar-Yosef, D. F. Kong, et al. “The association of anti-platelet factor 4/heparin antibodies with early and delayed thromboembolism after cardiac surgery.” J Thromb Haemost 15, no. 1 (January 2017): 57–65. https://doi.org/10.1111/jth.13533.Full Text Link to Item
-
Klinger, Rebecca Y., Mary Cooter, Miles Berger, Mihai V. Podgoreanu, Mark Stafford-Smith, Thomas L. Ortel, Ian J. Welsby, et al. “Effect of intravenous lidocaine on the transcerebral inflammatory response during cardiac surgery: a randomized-controlled trial.” Can J Anaesth 63, no. 11 (November 2016): 1223–32. https://doi.org/10.1007/s12630-016-0704-0.Full Text Link to Item
-
Krishnamoorthy, Arun, and Thomas Ortel. “A Bridge to Nowhere? Benefits and Risks for Periprocedural Anticoagulation in Atrial Fibrillation.” Curr Cardiol Rep 18, no. 10 (October 2016): 101. https://doi.org/10.1007/s11886-016-0779-9.Full Text Link to Item
-
Voora, Deepak, A Koneti Rao, Gauthami S. Jalagadugula, Rachel Myers, Emily Harris, Thomas L. Ortel, and Geoffrey S. Ginsburg. “Systems Pharmacogenomics Finds RUNX1 Is an Aspirin-Responsive Transcription Factor Linked to Cardiovascular Disease and Colon Cancer.” Ebiomedicine 11 (September 2016): 157–64. https://doi.org/10.1016/j.ebiom.2016.08.021.Full Text Link to Item
-
Cohen, Alexander T., Robert A. Harrington, Samuel Z. Goldhaber, Russell D. Hull, Brian L. Wiens, Alex Gold, Adrian F. Hernandez, C Michael Gibson, and C Michael APEX Investigators. “Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients.” N Engl J Med 375, no. 6 (August 11, 2016): 534–44. https://doi.org/10.1056/NEJMoa1601747.Full Text Link to Item
-
Gauthier, Karine, Grégoire Le Gal, Sudeep Shivakumar, David Anderson, Isabelle Chagnon, Susan Solymoss, Thomas Ortel, Erik Yeo, Clive Kearon, and Marc Rodger. “Inter-observer reliability of the HERDOO2 clinical decision rule.” Thromb Res 141 (May 2016): 136–38. https://doi.org/10.1016/j.thromres.2016.03.015.Full Text Link to Item
-
Pavon, Juliessa M., Soheir S. Adam, Zayd A. Razouki, Jennifer R. McDuffie, Paul F. Lachiewicz, Andrzej S. Kosinski, Christopher A. Beadles, Thomas L. Ortel, Avishek Nagi, and John W. Williams. “Effectiveness of Intermittent Pneumatic Compression Devices for Venous Thromboembolism Prophylaxis in High-Risk Surgical Patients: A Systematic Review.” J Arthroplasty 31, no. 2 (February 2016): 524–32. https://doi.org/10.1016/j.arth.2015.09.043.Full Text Link to Item
-
Douketis, James D., Vic Hasselblad, and Thomas L. Ortel. “Bridging Anticoagulation in Patients with Atrial Fibrillation.” N Engl J Med 374, no. 1 (January 7, 2016): 93–94. https://doi.org/10.1056/NEJMc1513255.Full Text Link to Item
-
Kahn, S. R., S. Shapiro, T. Ducruet, P. S. Wells, M. A. Rodger, M. J. Kovacs, D. Anderson, et al. “Medical compression stockings in the treatment of acute leg pain after proximal deep vein thrombosis: A randomized trial.” Vasomed 28, no. 1 (January 1, 2016): 46.
-
Rabinovich, Anat, Jacqueline M. Cohen, Mary Cushman, Susan R. Kahn, and Susan R. BioSOX Investigators. “Association between inflammation biomarkers, anatomic extent of deep venous thrombosis, and venous symptoms after deep venous thrombosis.” J Vasc Surg Venous Lymphat Disord 3, no. 4 (October 2015): 347-353.e1. https://doi.org/10.1016/j.jvsv.2015.04.005.Full Text Link to Item
-
Ortel, Thomas L., Doruk Erkan, and Craig S. Kitchens. “How I treat catastrophic thrombotic syndromes.” Blood 126, no. 11 (September 10, 2015): 1285–93. https://doi.org/10.1182/blood-2014-09-551978.Full Text Link to Item
-
Faiz, Ambarina S., Imran Khan, Michele G. Beckman, Paula Bockenstedt, John A. Heit, Roshni Kulkarni, Marilyn Manco-Johnson, Stephan Moll, Thomas L. Ortel, and Claire S. Philipp. “Characteristics and Risk Factors of Cancer Associated Venous Thromboembolism.” Thromb Res 136, no. 3 (September 2015): 535–41. https://doi.org/10.1016/j.thromres.2015.06.036.Full Text Link to Item
-
Streiff, Michael B., Bjorn Holmstrom, Aneel Ashrani, Paula L. Bockenstedt, Carolyn Chesney, Charles Eby, John Fanikos, et al. “Cancer-Associated Venous Thromboembolic Disease, Version 1.2015.” Journal of the National Comprehensive Cancer Network : Jnccn 13, no. 9 (September 2015): 1079–95. https://doi.org/10.6004/jnccn.2015.0133.Full Text
-
Douketis, James D., Alex C. Spyropoulos, Scott Kaatz, Richard C. Becker, Joseph A. Caprini, Andrew S. Dunn, David A. Garcia, et al. “Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation.” N Engl J Med 373, no. 9 (August 27, 2015): 823–33. https://doi.org/10.1056/NEJMoa1501035.Full Text Link to Item
-
Francis, C. W., C. M. Kessler, S. Z. Goldhaber, M. J. Kovacs, M. Monreal, M. V. Huisman, D. Bergqvist, et al. “Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study.” J Thromb Haemost 13, no. 6 (June 2015): 1028–35. https://doi.org/10.1111/jth.12923.Full Text Link to Item
-
Schulman, S., M. Zondag, L. Linkins, S. Pasca, Y. W. Cheung, M. de Sancho, A. Gallus, et al. “Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis.” J Thromb Haemost 13, no. 6 (June 2015): 1010–18. https://doi.org/10.1111/jth.12955.Full Text Link to Item
-
Steiner, Marie E., Paul M. Ness, Susan F. Assmann, Darrell J. Triulzi, Steven R. Sloan, Meghan Delaney, Suzanne Granger, et al. “Effects of red-cell storage duration on patients undergoing cardiac surgery.” N Engl J Med 372, no. 15 (April 9, 2015): 1419–29. https://doi.org/10.1056/NEJMoa1414219.Full Text Link to Item
-
Lewis, Deborah A., Sunil Suchindran, Michele G. Beckman, W Craig Hooper, Althea M. Grant, John A. Heit, Marilyn Manco-Johnson, et al. “Whole blood gene expression profiles distinguish clinical phenotypes of venous thromboembolism.” Thromb Res 135, no. 4 (April 2015): 659–65. https://doi.org/10.1016/j.thromres.2015.02.003.Full Text Link to Item
-
Jiang, W., S. H. Boyle, T. L. Ortel, Z. Samad, E. J. Velazquez, R. W. Harrison, J. Wilson, et al. “Platelet aggregation and mental stress induced myocardial ischemia: Results from the Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT) study.” American Heart Journal 169, no. 4 (April 1, 2015): 496-507.e1. https://doi.org/10.1016/j.ahj.2014.12.002.Full Text
-
Jiang, Wei, Stephen H. Boyle, Thomas L. Ortel, Zainab Samad, Eric J. Velazquez, Robert W. Harrison, Jennifer Wilson, et al. “Platelet aggregation and mental stress induced myocardial ischemia: Results from the Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT) study.” Am Heart J 169, no. 4 (April 2015): 496-507.e1. https://doi.org/10.1016/j.ahj.2014.12.002.Full Text Open Access Copy Link to Item
-
Rabinovich, A., J. M. Cohen, M. Cushman, P. S. Wells, M. A. Rodger, M. J. Kovacs, D. R. Anderson, et al. “Inflammation markers and their trajectories after deep vein thrombosis in relation to risk of post-thrombotic syndrome.” J Thromb Haemost 13, no. 3 (March 2015): 398–408. https://doi.org/10.1111/jth.12814.Full Text Link to Item
-
Welsby, Ian, and Thomas L. Ortel. “Is it time for individualized thromboprophylaxis regimens in the ICU?” Crit Care Med 43, no. 2 (February 2015): 500–501. https://doi.org/10.1097/CCM.0000000000000784.Full Text Link to Item
-
Arepally, Gowthami M., and Thomas L. Ortel. “Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?” Annu Rev Med 66 (2015): 241–53. https://doi.org/10.1146/annurev-med-051113-024633.Full Text Link to Item
-
Yusuf, Hussain R., W Craig Hooper, Scott D. Grosse, Christopher S. Parker, Sheree L. Boulet, and Thomas L. Ortel. “Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: a study among a U.S. cohort of commercial insurance enrollees.” Thromb Res 135, no. 1 (January 2015): 50–57. https://doi.org/10.1016/j.thromres.2014.10.012.Full Text Link to Item
-
Ortel, Thomas L., Michele Beckman, Lawrence Muhlbaier, Nimia Reyes, Althea Grant, James Tcheng, Ibrahim Saber, and Elizabeth Thames. “Venous Thromboembolism (VTE) Surveillance: Incidence, Characteristics, and Initial Treatment of VTE Patients.” Blood 124, no. 21 (December 6, 2014).Link to Item
-
Kahn, S. R., S. Shapiro, T. Ducruet, P. S. Wells, M. A. Rodger, M. J. Kovacs, D. Anderson, et al. “Graduated compression stockings to treat acute leg pain associated with proximal DVT. A randomised controlled trial.” Thromb Haemost 112, no. 6 (December 2014): 1137–41. https://doi.org/10.1160/TH14-05-0430.Full Text Link to Item
-
Samad, Zainab, Stephen Boyle, Mads Ersboll, Amit N. Vora, Ye Zhang, Richard C. Becker, Redford Williams, et al. “Sex differences in platelet reactivity and cardiovascular and psychological response to mental stress in patients with stable ischemic heart disease: insights from the REMIT study.” J Am Coll Cardiol 64, no. 16 (October 21, 2014): 1669–78. https://doi.org/10.1016/j.jacc.2014.04.087.Full Text Link to Item
-
Vavalle, J. P., C. P. Rusconi, S. Zelenkofske, W. A. Wargin, T. L. Ortel, J. H. Alexander, T. J. Povsic, and R. C. Becker. “The effect of the REG2 Anticoagulation System on thrombin generation kinetics: a pharmacodynamic and pharmacokinetic first-in-human study.” J Thromb Thrombolysis 38, no. 3 (October 2014): 275–84. https://doi.org/10.1007/s11239-014-1081-6.Full Text Link to Item
-
Yusuf, Hussain R., W Craig Hooper, Michele G. Beckman, Qing C. Zhang, James Tsai, and Thomas L. Ortel. “Risk of venous thromboembolism among hospitalizations of adults with selected autoimmune diseases.” J Thromb Thrombolysis 38, no. 3 (October 2014): 306–13. https://doi.org/10.1007/s11239-014-1050-0.Full Text Link to Item
-
McCrindle, Brian W., Jennifer S. Li, Cedric Manlhiot, James S. Tweddell, Therese M. Giglia, M Patricia Massicotte, Paul Monagle, et al. “Challenges and priorities for research: a report from the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH) Working Group on thrombosis in pediatric cardiology and congenital heart disease.” Circulation 130, no. 14 (September 30, 2014): 1192–1203. https://doi.org/10.1161/CIRCULATIONAHA.113.008428.Full Text Link to Item
-
Bertolaccini, Maria Laura, Olga Amengual, Laura Andreoli, Tatsuya Atsumi, Cecilia B. Chighizola, Ricardo Forastiero, Philip de Groot, et al. “14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends.” Autoimmun Rev 13, no. 9 (September 2014): 917–30. https://doi.org/10.1016/j.autrev.2014.05.001.Full Text Link to Item
-
Ellero-Simatos, S., J. P. Lewis, A. Georgiades, L. M. Yerges-Armstrong, A. L. Beitelshees, R. B. Horenstein, A. Dane, et al. “Pharmacometabolomics reveals that serotonin is implicated in aspirin response variability.” Cpt Pharmacometrics Syst Pharmacol 3, no. 7 (July 16, 2014): e125. https://doi.org/10.1038/psp.2014.22.Full Text Link to Item
-
Erkan, Doruk, Cassyanne L. Aguiar, Danieli Andrade, Hannah Cohen, Maria J. Cuadrado, Adriana Danowski, Roger A. Levy, et al. “14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends.” Autoimmun Rev 13, no. 6 (June 2014): 685–96. https://doi.org/10.1016/j.autrev.2014.01.053.Full Text Link to Item
-
Devreese, K. M. J., S. S. Pierangeli, B. de Laat, A. Tripodi, T. Atsumi, T. L. Ortel, and T. L. Subcommittee on Lupus Anticoagulant/Phospholipid/Dependent Antibodies. “Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH.” J Thromb Haemost 12, no. 5 (May 2014): 792–95. https://doi.org/10.1111/jth.12537.Full Text Link to Item
-
Hester, Willie, Caitlyn Fry, Daniel Gonzalez, Michael Cohen-Wolkowiez, Brant A. Inman, and Thomas L. Ortel. “Thromboprophylaxis with fondaparinux in high-risk postoperative patients with renal insufficiency.” Thromb Res 133, no. 4 (April 2014): 629–33. https://doi.org/10.1016/j.thromres.2013.11.019.Full Text Link to Item
-
Kahn, Susan R., Stan Shapiro, Philip S. Wells, Marc A. Rodger, Michael J. Kovacs, David R. Anderson, Vicky Tagalakis, et al. “Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial.” Lancet 383, no. 9920 (March 8, 2014): 880–88. https://doi.org/10.1016/S0140-6736(13)61902-9.Full Text Link to Item
-
Shivakumar, Sudeep, and James Douketis. “ACP Journal Club. Review: new oral factor Xa inhibitors reduce DVT compared with standard thromboprophylaxis after THR or TKR.” Ann Intern Med 160, no. 2 (January 21, 2014): JC3. https://doi.org/10.7326/0003-4819-160-2-201401210-02003.Full Text Link to Item
-
Philipp, Claire S., Ambarina S. Faiz, Michele G. Beckman, Althea Grant, Paula L. Bockenstedt, John A. Heit, Andra H. James, et al. “Differences in thrombotic risk factors in black and white women with adverse pregnancy outcome.” Thromb Res 133, no. 1 (January 2014): 108–11. https://doi.org/10.1016/j.thromres.2013.10.035.Full Text Link to Item
-
Kimmel, Stephen E., Benjamin French, Scott E. Kasner, Julie A. Johnson, Jeffrey L. Anderson, Brian F. Gage, Yves D. Rosenberg, et al. “A pharmacogenetic versus a clinical algorithm for warfarin dosing.” N Engl J Med 369, no. 24 (December 12, 2013): 2283–93. https://doi.org/10.1056/NEJMoa1310669.Full Text Link to Item
-
Streiff, Michael B., Paula L. Bockenstedt, Spero R. Cataland, Carolyn Chesney, Charles Eby, John Fanikos, Annemarie E. Fogerty, et al. “Venous thromboembolic disease.” J Natl Compr Canc Netw 11, no. 11 (November 2013): 1402–29. https://doi.org/10.6004/jnccn.2013.0163.Full Text Link to Item
-
Voora, Deepak, Derek Cyr, Joseph Lucas, Jen-Tsan Chi, Jennifer Dungan, Timothy A. McCaffrey, Richard Katz, et al. “Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events.” J Am Coll Cardiol 62, no. 14 (October 1, 2013): 1267–76. https://doi.org/10.1016/j.jacc.2013.05.073.Full Text Link to Item
-
Spyropoulos, Alex C., and Thomas L. Ortel. “Antithrombotic therapy and invasive procedures.” N Engl J Med 369, no. 11 (September 12, 2013): 1078. https://doi.org/10.1056/NEJMc1308259.Full Text Link to Item
-
Adam, Soheir S., Jennifer R. McDuffie, Paul F. Lachiewicz, Thomas L. Ortel, and John W. Williams. “Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review.” Ann Intern Med 159, no. 4 (August 20, 2013): 275–84. https://doi.org/10.7326/0003-4819-159-4-201308200-00008.Full Text Link to Item
-
Bennett, Charles L., Sony Jacob, Brianne L. Dunn, Peter Georgantopoulos, X Long Zheng, Hau C. Kwaan, June M. McKoy, et al. “Ticlopidine-associated ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in 22 persons in Japan: a report from the Southern Network on Adverse Reactions (SONAR).” Br J Haematol 161, no. 6 (June 2013): 896–98. https://doi.org/10.1111/bjh.12303.Full Text Link to Item
-
Jiang, Wei, Eric J. Velazquez, Maragatha Kuchibhatla, Zainab Samad, Stephen H. Boyle, Cynthia Kuhn, Richard C. Becker, et al. “Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial.” Jama 309, no. 20 (May 22, 2013): 2139–49. https://doi.org/10.1001/jama.2013.5566.Full Text Link to Item
-
Piazza, Gregory, Frederick A. Anderson, Thomas L. Ortel, Michael J. Cox, David J. Rosenberg, Shahram Rahimian, William J. Pendergast, et al. “Randomized trial of physician alerts for thromboprophylaxis after discharge.” Am J Med 126, no. 5 (May 2013): 435–42. https://doi.org/10.1016/j.amjmed.2012.09.020.Full Text Link to Item
-
Adam, Soheir S., Thomas L. Ortel, and John W. Williams. “Comparative effectiveness of warfarin and new anticoagulants.” Ann Intern Med 158, no. 8 (April 16, 2013): 637–38. https://doi.org/10.7326/0003-4819-158-8-201304160-00017.Full Text Link to Item
-
Lee, Grace M., Ian J. Welsby, Barbara Phillips-Bute, Thomas L. Ortel, and Gowthami M. Arepally. “High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass.” Blood 121, no. 15 (April 11, 2013): 2828–35. https://doi.org/10.1182/blood-2012-11-469130.Full Text Link to Item
-
Goldhaber, Samuel Z., Thomas L. Ortel, Carolyn A. Berry, Stephanie A. Stowell, and Allison J. Gardner. “Improving clinician performance of inpatient venous thromboembolism risk assessment and prophylaxis.” Hosp Pract (1995) 41, no. 2 (April 2013): 123–31. https://doi.org/10.3810/hp.2013.04.1061.Full Text Link to Item
-
Landi, Daniel, Michele G. Beckman, Nirmish R. Shah, Paula Bockenstedt, Althea M. Grant, John A. Heit, Nigel S. Key, et al. “Characteristics of abdominal vein thrombosis in children and adults.” Thromb Haemost 109, no. 4 (April 2013): 625–32. https://doi.org/10.1160/TH12-08-0568.Full Text Open Access Copy Link to Item
-
Jiang, Wei, Zainab Samad, Stephen Boyle, Richard C. Becker, Redford Williams, Cynthia Kuhn, Thomas L. Ortel, et al. “Prevalence and clinical characteristics of mental stress-induced myocardial ischemia in patients with coronary heart disease.” J Am Coll Cardiol 61, no. 7 (February 19, 2013): 714–22. https://doi.org/10.1016/j.jacc.2012.11.037.Full Text Link to Item
-
Suwanawiboon, B., and T. L. Ortel. “Anticoagulation in the Perioperative Period,” January 1, 2013, 673–87. https://doi.org/10.1016/B978-1-4557-2296-9.00037-3.Full Text
-
Berger, Jeffrey S., Richard C. Becker, Cynthia Kuhn, Michael J. Helms, Thomas L. Ortel, and Redford Williams. “Hyperreactive platelet phenotypes: relationship to altered serotonin transporter number, transport kinetics and intrinsic response to adrenergic co-stimulation.” Thromb Haemost 109, no. 1 (January 2013): 85–92. https://doi.org/10.1160/TH12-03-0202.Full Text Link to Item
-
Boyle, Stephen H., Zainab Samad, Richard C. Becker, Redford Williams, Cynthia Kuhn, Thomas L. Ortel, Maragatha Kuchibhatla, et al. “Depressive symptoms and mental stress-induced myocardial ischemia in patients with coronary heart disease.” Psychosom Med 75, no. 9 (2013): 822–31. https://doi.org/10.1097/PSY.0b013e3182a893ae.Full Text Link to Item
-
Ortel, Thomas L. “Perioperative management of patients on chronic antithrombotic therapy.” Blood 120, no. 24 (December 6, 2012): 4699–4705. https://doi.org/10.1182/blood-2012-05-423228.Full Text Link to Item
-
Adam, Soheir S., Jennifer R. McDuffie, Thomas L. Ortel, and John W. Williams. “Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review.” Ann Intern Med 157, no. 11 (December 4, 2012): 796–807. https://doi.org/10.7326/0003-4819-157-10-201211200-00532.Full Text Link to Item
-
Ortel, T. L., C. S. Kitchens, D. Erkan, L. R. Brandão, S. Hahn, A. H. James, R. Kulkarni, M. J. Manco-Johnson, M. Pericak-Vance, and J. Vance. “Clinical causes and treatment of the thrombotic storm.” Expert Review of Hematology 5, no. 6 (December 1, 2012): 653–59.
-
Ortel, Thomas L., Craig S. Kitchens, Doruk Erkan, Leonardo R. Brandão, Susan Hahn, Andra H. James, Roshni Kulkarni, Marilyn J. Manco-Johnson, Margaret Pericak-Vance, and Jeffery Vance. “Clinical causes and treatment of the thrombotic storm.” Expert Rev Hematol 5, no. 6 (December 2012): 653–59. https://doi.org/10.1586/ehm.12.56.Full Text Link to Item
-
Chan, Mark Y., Min Lin, Joseph Lucas, Arthur Moseley, J Will Thompson, Derek Cyr, Hitoshi Ueda, Mariko Kajikawa, Thomas L. Ortel, and Richard C. Becker. “Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor.” Thromb Haemost 108, no. 6 (December 2012): 1180–91. https://doi.org/10.1160/TH12-05-0310.Full Text Link to Item
-
Jacob, Sony, Brianne L. Dunn, Zaina P. Qureshi, Nicholas Bandarenko, Hau C. Kwaan, Dilip K. Pandey, June M. McKoy, et al. “Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR).” Semin Thromb Hemost 38, no. 8 (November 2012): 845–53. https://doi.org/10.1055/s-0032-1328894.Full Text Link to Item
-
Shah, Nirmish, Courtney Thornburg, Marilyn J. Telen, and Thomas L. Ortel. “Characterization of the hypercoagulable state in patients with sickle cell disease.” Thromb Res 130, no. 5 (November 2012): e241–45. https://doi.org/10.1016/j.thromres.2012.08.307.Full Text Link to Item
-
Harrison, Robert W., Thomas L. Ortel, and Richard C. Becker. “To bridge or not to bridge: these are the questions.” J Thromb Thrombolysis 34, no. 1 (July 2012): 31–35. https://doi.org/10.1007/s11239-012-0732-8.Full Text Link to Item
-
Kaatz, Scott, Peter A. Kouides, David A. Garcia, Alex C. Spyropolous, Mark Crowther, Jim D. Douketis, Anthony K. C. Chan, et al. “Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.” Am J Hematol 87 Suppl 1 (May 2012): S141–45. https://doi.org/10.1002/ajh.23202.Full Text Link to Item
-
Ortel, Thomas L. “Antiphospholipid syndrome: laboratory testing and diagnostic strategies.” Am J Hematol 87 Suppl 1, no. Suppl 1 (May 2012): S75–81. https://doi.org/10.1002/ajh.23196.Full Text Link to Item
-
Spyropoulos, A. C., J. D. Douketis, G. Gerotziafas, S. Kaatz, T. L. Ortel, S. Schulman, and S. Subcommittee on Control of Anticoagulation of the SSC of the ISTH. “Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy.” J Thromb Haemost 10, no. 4 (April 2012): 692–94. https://doi.org/10.1111/j.1538-7836.2012.04630.x.Full Text Link to Item
-
Voora, Deepak, Thomas L. Ortel, Joseph E. Lucas, Jen-Tsan Chi, Richard C. Becker, and Geoffrey S. Ginsburg. “Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy.” J Thromb Thrombolysis 33, no. 3 (April 2012): 246–57. https://doi.org/10.1007/s11239-012-0683-0.Full Text Link to Item
-
Falck-Ytter, Yngve, Charles W. Francis, Norman A. Johanson, Catherine Curley, Ola E. Dahl, Sam Schulman, Thomas L. Ortel, Stephen G. Pauker, and Clifford W. Colwell. “Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.” Chest 141, no. 2 Suppl (February 2012): e278S-e325S. https://doi.org/10.1378/chest.11-2404.Full Text Link to Item
-
Ortel, Thomas L. “Laboratory diagnosis of the lupus anticoagulant.” Curr Rheumatol Rep 14, no. 1 (February 2012): 64–70. https://doi.org/10.1007/s11926-011-0225-3.Full Text Link to Item
-
Ortel, Thomas L. “Perioperative management of patients on chronic antithrombotic therapy.” Hematology Am Soc Hematol Educ Program 2012 (2012): 529–35. https://doi.org/10.1182/asheducation-2012.1.529.Full Text Link to Item
-
Jiang, Wei, Eric J. Velazquez, Zainab Samad, Maragatha Kuchibhatla, Carolyn Martsberger, Joseph Rogers, Redford Williams, et al. “Responses of mental stress-induced myocardial ischemia to escitalopram treatment: background, design, and method for the Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment trial.” Am Heart J 163, no. 1 (January 2012): 20–26. https://doi.org/10.1016/j.ahj.2011.09.018.Full Text Link to Item
-
Lewis, Deborah A., Gregg J. Stashenko, Olga M. Akay, Lulit I. Price, Kouros Owzar, Geoffrey S. Ginsburg, Jen-Tsan Chi, and Thomas L. Ortel. “Whole blood gene expression analyses in patients with single versus recurrent venous thromboembolism.” Thromb Res 128, no. 6 (December 2011): 536–40. https://doi.org/10.1016/j.thromres.2011.06.003.Full Text Link to Item
-
Potti, A., A. Bild, H. K. Dressman, D. A. Lewis, J. R. Nevins, and T. L. Ortel. “Gene-expression patterns predict phenotypes of immune-mediated thrombosis (Blood (2006) 107, 4, (1391-1396)).” Blood 118, no. 16 (October 20, 2011): 4497. https://doi.org/10.1182/blood-2011-08-375030.Full Text
-
Miriovsky, Benjamin J., and Thomas L. Ortel. “Heparin-induced thrombocytopenia in cancer.” J Natl Compr Canc Netw 9, no. 7 (July 1, 2011): 781–87. https://doi.org/10.6004/jnccn.2011.0063.Full Text Link to Item
-
Streiff, Michael B., Paula L. Bockenstedt, Spero R. Cataland, Carolyn Chesney, Charles Eby, John Fanikos, Patrick F. Fogarty, et al. “Venous thromboembolic disease.” J Natl Compr Canc Netw 9, no. 7 (July 1, 2011): 714–77. https://doi.org/10.6004/jnccn.2011.0062.Full Text Link to Item
-
Davidson, Simon J., Thomas L. Ortel, and Larry J. Smith. “Performance of a new, rapid, automated immunoassay for the detection of anti-platelet factor 4/heparin complex antibodies.” Blood Coagul Fibrinolysis 22, no. 4 (June 2011): 340–44. https://doi.org/10.1097/MBC.0b013e328344f7e9.Full Text Link to Item
-
Kitchens, Craig S., Doruk Erkan, Leonardo R. Brandão, Susan Hahn, Andra H. James, Roshni Kulkarni, Margaret Pericak-Vance, Jeffery Vance, and Thomas L. Ortel. “Thrombotic storm revisited: preliminary diagnostic criteria suggested by the thrombotic storm study group.” Am J Med 124, no. 4 (April 2011): 290–96. https://doi.org/10.1016/j.amjmed.2010.10.018.Full Text Link to Item
-
Bhandari, Mohit, Frederick A. Ofosu, Nigel Mackman, Craig Jackson, Cataldo Doria, John E. Humphries, Sateesh C. Babu, et al. “Safety and efficacy of thrombin-JMI: a multidisciplinary expert group consensus.” Clin Appl Thromb Hemost 17, no. 1 (February 2011): 39–45. https://doi.org/10.1177/1076029610385674.Full Text Link to Item
-
Erkan, D., R. Derksen, R. Levy, S. Machin, T. Ortel, S. Pierangeli, R. Roubey, and M. Lockshin. “Antiphospholipid Syndrome Clinical Research Task Force report.” Lupus 20, no. 2 (February 2011): 219–24. https://doi.org/10.1177/0961203310395053.Full Text Link to Item
-
Pierangeli, S. S., P. G. de Groot, J. Dlott, E. Favaloro, E. N. Harris, G. Lakos, T. Ortel, et al. “'Criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010.” Lupus 20, no. 2 (February 2011): 182–90. https://doi.org/10.1177/0961203310395055.Full Text Link to Item
-
Chudasama, Shalini L., Benjamin Espinasse, Fred Hwang, Rui Qi, Manali Joglekar, Galyna Afonina, Mark R. Wiesner, Ian J. Welsby, Thomas L. Ortel, and Gowthami M. Arepally. “Heparin modifies the immunogenicity of positively charged proteins.” Blood 116, no. 26 (December 23, 2010): 6046–53. https://doi.org/10.1182/blood-2010-06-292938.Full Text Link to Item
-
Cuker, A., G. Arepally, M. A. Crowther, L. Rice, F. Datko, K. Hook, K. J. Propert, et al. “The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion.” J Thromb Haemost 8, no. 12 (December 2010): 2642–50. https://doi.org/10.1111/j.1538-7836.2010.04059.x.Full Text Link to Item
-
Lindhoff-Last, Edelgard, Meyer Michel Samama, Thomas L. Ortel, Jeffrey I. Weitz, and Theodore E. Spiro. “Assays for measuring rivaroxaban: their suitability and limitations.” Ther Drug Monit 32, no. 6 (December 2010): 673–79. https://doi.org/10.1097/FTD.0b013e3181f2f264.Full Text Link to Item
-
Heit, J. A., M. Beckman, P. Bockenstedt, A. Grant, N. Key, R. Kulkarni, M. Manco-Johnson, S. Moll, T. Ortel, and C. Philipp. “Comparison of characteristics from White- and Black-Americans with venous thromboembolism: A cross sectional study.” American Journal of Hematology 85, no. 11 (November 1, 2010): 908–908. https://doi.org/10.1002/ajh.21844.Full Text
-
Whitlatch, Nicole L., David F. Kong, Ara D. Metjian, Gowthami M. Arepally, and Thomas L. Ortel. “Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia.” Blood 116, no. 10 (September 9, 2010): 1761–66. https://doi.org/10.1182/blood-2010-01-262659.Full Text Link to Item
-
Lou, Junyang, Thomas J. Povsic, Jason D. Allen, Stacie D. Adams, Shelley Myles, Aijing Z. Starr, Thomas L. Ortel, and Richard C. Becker. “The effect of aspirin on endothelial progenitor cell biology: preliminary investigation of novel properties.” Thromb Res 126, no. 3 (September 2010): e175–79. https://doi.org/10.1016/j.thromres.2009.11.017.Full Text Link to Item
-
Heit, John A., Michele G. Beckman, Paula L. Bockenstedt, Althea M. Grant, Nigel S. Key, Roshni Kulkarni, Marilyn J. Manco-Johnson, et al. “Comparison of characteristics from White- and Black-Americans with venous thromboembolism: a cross-sectional study.” Am J Hematol 85, no. 7 (July 2010): 467–71. https://doi.org/10.1002/ajh.21735.Full Text Link to Item
-
Perry, S., and T. L. Ortel. “Nephrology,” May 5, 2010, 227–34. https://doi.org/10.1002/9781444306286.ch22.Full Text
-
Brummett, Beverly H., Stephen H. Boyle, Thomas L. Ortel, Richard C. Becker, Ilene C. Siegler, and Redford B. Williams. “Associations of depressive symptoms, trait hostility, and gender with C-reactive protein and interleukin-6 response after emotion recall.” Psychosom Med 72, no. 4 (May 2010): 333–39. https://doi.org/10.1097/PSY.0b013e3181d2f104.Full Text Link to Item
-
Beckman, Michele G., W Craig Hooper, Sara E. Critchley, and Thomas L. Ortel. “Venous thromboembolism: a public health concern.” Am J Prev Med 38, no. 4 Suppl (April 2010): S495–501. https://doi.org/10.1016/j.amepre.2009.12.017.Full Text Link to Item
-
Slichter, Sherrill J., Richard M. Kaufman, Susan F. Assmann, Jeffrey McCullough, Darrell J. Triulzi, Ronald G. Strauss, Terry B. Gernsheimer, et al. “Dose of prophylactic platelet transfusions and prevention of hemorrhage.” N Engl J Med 362, no. 7 (February 18, 2010): 600–613. https://doi.org/10.1056/NEJMoa0904084.Full Text Link to Item
-
Ortel, Thomas L. “Acquired thrombotic risk factors in the critical care setting.” Crit Care Med 38, no. 2 Suppl (February 2010): S43–50. https://doi.org/10.1097/CCM.0b013e3181c9ccc8.Full Text Link to Item
-
Arepally, Gowthami M., and Thomas L. Ortel. “Heparin-induced thrombocytopenia.” Annu Rev Med 61 (2010): 77–90. https://doi.org/10.1146/annurev.med.042808.171814.Full Text Link to Item
-
Welsby, Ian J., John Um, Carmelo A. Milano, Thomas L. Ortel, and Gowthami Arepally. “Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia.” Anesth Analg 110, no. 1 (January 1, 2010): 30–35. https://doi.org/10.1213/ANE.0b013e3181c3c1cd.Full Text Link to Item
-
Kuderer, Nicole M., Thomas L. Ortel, and Charles W. Francis. “Impact of venous thromboembolism and anticoagulation on cancer and cancer survival.” J Clin Oncol 27, no. 29 (October 10, 2009): 4902–11. https://doi.org/10.1200/JCO.2009.22.4584.Full Text Link to Item
-
Pengo, V., A. Tripodi, G. Reber, J. H. Rand, T. L. Ortel, M. Galli, P. G. De Groot, and P. G. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. “Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis.” J Thromb Haemost 7, no. 10 (October 2009): 1737–40. https://doi.org/10.1111/j.1538-7836.2009.03555.x.Full Text Link to Item
-
Perry, S. L., N. L. Whitlatch, and T. L. Ortel. “Heparin-dependent platelet factor 4 antibodies and the impact of renal function on clinical outcomes: a retrospective study in hospitalized patients.” J Thromb Thrombolysis 28, no. 2 (August 2009): 146–50. https://doi.org/10.1007/s11239-008-0265-3.Full Text Link to Item
-
Kessler, Craig M., and Thomas L. Ortel. “Recent developments in topical thrombins.” Thromb Haemost 102, no. 1 (July 2009): 15–24. https://doi.org/10.1160/TH09-01-0034.Full Text Link to Item
-
Nichols, William L., Margaret E. Rick, Thomas L. Ortel, Robert R. Montgomery, J Evan Sadler, Barbara P. Yawn, Andra H. James, Mae B. Hultin, Marilyn J. Manco-Johnson, and Mark Weinstein. “Clinical and laboratory diagnosis of von Willebrand disease: a synopsis of the 2008 NHLBI/NIH guidelines.” Am J Hematol 84, no. 6 (June 2009): 366–70. https://doi.org/10.1002/ajh.21405.Full Text Link to Item
-
Zakarija, Anaadriana, Hau C. Kwaan, Joel L. Moake, Nicholas Bandarenko, Dilip K. Pandey, June M. McKoy, Paul R. Yarnold, et al. “Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008).” Kidney Int Suppl, no. 112 (February 2009): S20–24. https://doi.org/10.1038/ki.2008.613.Full Text Link to Item
-
Cuker, Adam, and Thomas L. Ortel. “ASH evidence-based guidelines: is the IgG-specific anti-PF4/heparin ELISA superior to the polyspecific ELISA in the laboratory diagnosis of HIT?” Hematology Am Soc Hematol Educ Program, 2009, 250–52. https://doi.org/10.1182/asheducation-2009.1.250.Full Text Link to Item
-
Nichols, W. L., M. B. Hultln, A. H. James, M. J. Manco-johnson, R. R. Montgomery, T. L. Ortel, M. E. Rick, J. E. Sadler, M. Weinstein, and B. P. Yawn. “von Willebrand factor content in Alphanate® (Laurence J. Logan) - Reply.” Haemophilia 15, no. 1 (2009): 370–71. https://doi.org/10.1111/j.1365-2516.2008.01903.x.Full Text
-
Ortel, Thomas L. “Heparin-induced thrombocytopenia: when a low platelet count is a mandate for anticoagulation.” Hematology Am Soc Hematol Educ Program, 2009, 225–32. https://doi.org/10.1182/asheducation-2009.1.225.Full Text Link to Item
-
Ramiah, V., and T. L. Ortel. “Molecular testing for coagulopathies,” December 1, 2008, 623–36. https://doi.org/10.1007/978-1-59745-405-6_23.Full Text
-
Whitlatch, Nicole L., Stephanie L. Perry, and Thomas L. Ortel. “Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia.” Thromb Haemost 100, no. 4 (October 2008): 678–84. https://doi.org/10.1160/th08-02-0118.Full Text Link to Item
-
Wagman, Lawrence D., Melissa F. Baird, Charles L. Bennett, Paula L. Bockenstedt, Spero R. Cataland, John Fanikos, Patrick F. Fogarty, et al. “Venous thromboembolic disease. NCCN. Clinical practice guidelines in oncology.” J Natl Compr Canc Netw 6, no. 8 (September 2008): 716–53. https://doi.org/10.6004/jnccn.2008.0055.Full Text Link to Item
-
O’Shea, Susan I., Murat O. Arcasoy, Gregory Samsa, Sandra E. Cummings, Elizabeth H. Thames, Richard S. Surwit, and Thomas L. Ortel. “Direct-to-patient expert system and home INR monitoring improves control of oral anticoagulation.” J Thromb Thrombolysis 26, no. 1 (August 2008): 14–21. https://doi.org/10.1007/s11239-007-0068-y.Full Text Link to Item
-
Nichols, W. L., M. B. Hultin, A. H. James, M. J. Manco-Johnson, R. R. Montgomery, T. L. Ortel, M. E. Rick, J. E. Sadler, M. Weinstein, and B. P. Yawn. “von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA).” Haemophilia 14, no. 2 (March 2008): 171–232. https://doi.org/10.1111/j.1365-2516.2007.01643.x.Full Text Link to Item
-
Whitlatch, Nicole L., and Thomas L. Ortel. “Thrombophilias: when should we test and how does it help?” Semin Respir Crit Care Med 29, no. 1 (February 2008): 25–39. https://doi.org/10.1055/s-2008-1047560.Full Text Link to Item
-
Thornburg, Courtney D., Natalia Dixon, Kristin Paulyson-Nuñez, and Thomas Ortel. “Thrombophilia screening in asymptomatic children.” Thromb Res 121, no. 5 (2008): 597–604. https://doi.org/10.1016/j.thromres.2007.06.001.Full Text Link to Item
-
Ortel, Thomas L. “Prevention and treatment of deep venous thrombosis.” Vascular 16 Suppl 1 (2008): S64–70.Link to Item
-
Bennett-Guerrero, Elliott, Tim H. Veldman, Allan Doctor, Marilyn J. Telen, Thomas L. Ortel, T Scott Reid, Melissa A. Mulherin, et al. “Evolution of adverse changes in stored RBCs.” Proc Natl Acad Sci U S A 104, no. 43 (October 23, 2007): 17063–68. https://doi.org/10.1073/pnas.0708160104.Full Text Link to Item
-
Bennett, Charles L., Benjamin Kim, Anaadriana Zakarija, Nicholas Bandarenko, Dilip K. Pandey, Charlie G. Buffie, June M. McKoy, et al. “Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project.” J Am Coll Cardiol 50, no. 12 (September 18, 2007): 1138–43. https://doi.org/10.1016/j.jacc.2007.04.093.Full Text Link to Item
-
Schroder, Jacob N., Mani A. Daneshmand, Nestor R. Villamizar, Rebecca P. Petersen, Laura J. Blue, Ian J. Welsby, Andrew J. Lodge, Thomas L. Ortel, Joseph G. Rogers, and Carmelo A. Milano. “Heparin-induced thrombocytopenia in left ventricular assist device bridge-to-transplant patients.” Ann Thorac Surg 84, no. 3 (September 2007): 841–45. https://doi.org/10.1016/j.athoracsur.2007.03.049.Full Text Link to Item
-
Krakow, Elizabeth F., Ranjit Goudar, Elizabeth Petzold, Shayela Suvarna, Michael Last, Ian J. Welsby, Thomas L. Ortel, and Gowthami M. Arepally. “Influence of sample collection and storage on the detection of platelet factor 4-heparin antibodies.” Am J Clin Pathol 128, no. 1 (July 2007): 150–55. https://doi.org/10.1309/RFQK57F5QMURQ1HY.Full Text Link to Item
-
Welsby, Ian J., and Thomas L. Ortel. “Invited commentary.” Ann Thorac Surg 84, no. 1 (July 2007): 168–69. https://doi.org/10.1016/j.athoracsur.2007.04.021.Full Text Link to Item
-
Ramot, Yuval, Deborah A. Lewis, Thomas L. Ortel, Mike Streicker, Glenda Moser, Susan Elmore, Sandra M. Ward, Shyamal Peddada, and Abraham Nyska. “Age and dose sensitivities in the 2-butoxyethanol F344 rat model of hemolytic anemia and disseminated thrombosis.” Exp Toxicol Pathol 58, no. 5 (April 2007): 311–22. https://doi.org/10.1016/j.etp.2006.11.003.Full Text Link to Item
-
Dowling, N. F., M. G. Beckman, M. Manco-Johnson, K. Hassell, C. S. Philipp, L. A. Michaels, S. Moll, et al. “The U.S. Thrombosis and Hemostasis Centers pilot sites program.” J Thromb Thrombolysis 23, no. 1 (February 2007): 1–7. https://doi.org/10.1007/s11239-006-9002-y.Full Text Link to Item
-
Arepally, G. M., and T. L. Ortel. “The authors reply [21].” New England Journal of Medicine 355, no. 24 (December 14, 2006): 2598–99. https://doi.org/10.1056/NEJMc062561.Full Text
-
Perry, Stephanie L., Susan I. O’Shea, Stephen Byrne, Lynda A. Szczech, and Thomas L. Ortel. “A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients.” Thromb Haemost 96, no. 6 (December 2006): 750–55.Link to Item
-
Wagman, Lawrence D., Melissa F. Baird, Charles L. Bennett, Paula L. Bockenstedt, Spero R. Cataland, John Fanikos, Patrick F. Fogarty, et al. “Venous thromboembolic disease. Clinical practice guidelines in oncology.” J Natl Compr Canc Netw 4, no. 9 (October 2006): 838–69. https://doi.org/10.6004/jnccn.2006.0071.Full Text Link to Item
-
James, Andra H., Leo R. Brancazio, Thomas R. Gehrig, Andrew Wang, and Thomas L. Ortel. “Low-molecular-weight heparin for thromboprophylaxis in pregnant women with mechanical heart valves.” J Matern Fetal Neonatal Med 19, no. 9 (September 2006): 543–49. https://doi.org/10.1080/14767050600886666.Full Text Link to Item
-
Arepally, Gowthami M., and Thomas L. Ortel. “Clinical practice. Heparin-induced thrombocytopenia.” N Engl J Med 355, no. 8 (August 24, 2006): 809–17. https://doi.org/10.1056/NEJMcp052967.Full Text Link to Item
-
Welsby, Ian J., Kuiran Jiao, Thomas L. Ortel, Charles S. Brudney, Anthony M. Roche, Elliott Bennett-Guerrero, and Tong J. Gan. “The kaolin-activated Thrombelastograph predicts bleeding after cardiac surgery.” J Cardiothorac Vasc Anesth 20, no. 4 (August 2006): 531–35. https://doi.org/10.1053/j.jvca.2005.04.013.Full Text Link to Item
-
Hayward, C. P. M., P. Harrison, M. Cattaneo, T. L. Ortel, and A. K. Rao. “Platelet function analyzer (PFA)-100® closure time in the evaluation of platelet disorders and platelet function: Reply to a rebuttal [15].” Journal of Thrombosis and Haemostasis 4, no. 6 (June 1, 2006): 1433–34. https://doi.org/10.1111/j.1538-7836.2006.01992.x.Full Text
-
Hayward, C. P. M., P. Harrison, M. Cattaneo, T. L. Ortel, and A. K. Rao. “Platelet function analyzer (PFA)-100® closure time in the evaluation of platelet disorders and platelet function: Reply to a rebuttal [14].” Journal of Thrombosis and Haemostasis 4, no. 6 (June 1, 2006): 1432. https://doi.org/10.1111/j.1538-7836.2006.01927.x.Full Text
-
Lewis, D. A., M. L. Pound, and T. L. Ortel. “The reactivity of paired plasma and serum samples are comparable in the anticardiolipin and anti-β2-glycoprotein-1 ELISAs. Reply to a rebuttal [17].” Journal of Thrombosis and Haemostasis 4, no. 6 (June 1, 2006): 1435–37. https://doi.org/10.1111/j.1538-7836.2006.01984.x.Full Text
-
Spyropoulos, A. C., A. G. G. Turpie, A. S. Dunn, J. Spandorfer, J. Douketis, A. Jacobson, F. J. Frost, and F. J. REGIMEN Investigators. “Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry.” J Thromb Haemost 4, no. 6 (June 2006): 1246–52. https://doi.org/10.1111/j.1538-7836.2006.01908.x.Full Text Link to Item
-
Potti, Anil, Andrea Bild, Holly K. Dressman, Deborah A. Lewis, Joseph R. Nevins, and Thomas L. Ortel. “Gene-expression patterns predict phenotypes of immune-mediated thrombosis.” Blood 107, no. 4 (February 15, 2006): 1391–96. https://doi.org/10.1182/blood-2005-07-2669.Full Text Link to Item
-
Hayward, C. P. M., P. Harrison, M. Cattaneo, T. L. Ortel, A. K. Rao, and A. K. Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. “Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function.” J Thromb Haemost 4, no. 2 (February 2006): 312–19. https://doi.org/10.1111/j.1538-7836.2006.01771.x.Full Text Link to Item
-
James, A. H., L. R. Brancazio, and T. L. Ortel. “Thrombophilia in pregnancy: Maternal and fetal implications.” Current Women’S Health Reviews 2, no. 1 (February 1, 2006): 51–59. https://doi.org/10.2174/157340406775486265.Full Text
-
Ortel, Thomas L. “The antiphospholipid syndrome: what are we really measuring? How do we measure it? And how do we treat it?” J Thromb Thrombolysis 21, no. 1 (February 2006): 79–83. https://doi.org/10.1007/s11239-006-5581-x.Full Text Link to Item
-
Lewis, D. A., M. L. Pound, and T. L. Ortel. “The reactivity of paired plasma and serum samples are comparable in the anticardiolipin and anti-beta2-glycoprotein-1 ELISAs.” J Thromb Haemost 4, no. 1 (January 2006): 265–67. https://doi.org/10.1111/j.1538-7836.2005.01721.x.Full Text Link to Item
-
Lewis, Deborah A., Abraham Nyska, Anil Potti, Heather A. Hoke, Keith F. Klemp, Sandra M. Ward, Shyamal D. Peddada, Jogin Wu, and Thomas L. Ortel. “Hemostatic activation in a chemically induced rat model of severe hemolysis and thrombosis.” Thromb Res 118, no. 6 (2006): 747–53. https://doi.org/10.1016/j.thromres.2005.11.010.Full Text Link to Item
-
Welty-Wolf, Karen E., Martha S. Carraway, Thomas L. Ortel, Andrew J. Ghio, Steven Idell, Jack Egan, Xiaoyun Zhu, Jin-an Jiao, Hing C. Wong, and Claude A. Piantadosi. “Blockade of tissue factor-factor X binding attenuates sepsis-induced respiratory and renal failure.” Am J Physiol Lung Cell Mol Physiol 290, no. 1 (January 2006): L21–31. https://doi.org/10.1152/ajplung.00155.2005.Full Text Link to Item
-
Krakow, Elizabeth, and Thomas L. Ortel. “Continuing anticoagulation following venous thromboembolism.” Jama 294, no. 24 (December 28, 2005): 3088. https://doi.org/10.1001/jama.294.24.3088-a.Full Text Link to Item
-
Perry, Stephanie L., Gregory P. Samsa, and Thomas L. Ortel. “Point-of-care testing of the international normalized ratio in patients with antiphospholipid antibodies.” Thromb Haemost 94, no. 6 (December 2005): 1196–1202. https://doi.org/10.1160/TH05-06-0400.Full Text Link to Item
-
Potti, Anil, Veshana Ramiah, and Thomas L. Ortel. “Thrombophilia and thrombosis in thrombotic thrombocytopenic purpura.” Semin Thromb Hemost 31, no. 6 (December 2005): 652–58. https://doi.org/10.1055/s-2005-925471.Full Text Link to Item
-
Bennett-Guerrero, Elliott, Thomas F. Slaughter, William D. White, Ian J. Welsby, Charles S. Greenberg, Habib El-Moalem, and Thomas L. Ortel. “Preoperative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery.” J Thorac Cardiovasc Surg 130, no. 6 (December 2005): 1567–72. https://doi.org/10.1016/j.jtcvs.2005.07.052.Full Text Link to Item
-
Marder, V. J., T. L. Ortel, A. Grollman, and A. A. K. Hasan. “Thrombosis Research: Preface.” Thrombosis Research 117, no. 1–2 (November 18, 2005): 1–3. https://doi.org/10.1016/j.thromres.2005.09.002.Full Text
-
Haynes, Barton F., Judith Fleming, E William St Clair, Herman Katinger, Gabriela Stiegler, Renate Kunert, James Robinson, et al. “Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.” Science 308, no. 5730 (June 24, 2005): 1906–8. https://doi.org/10.1126/science.1111781.Full Text Link to Item
-
Lewis, Deborah A., Niels Bovenschen, Koen Mertens, Jan Voorberg, and Thomas L. Ortel. “Phospholipid vesicles interfere with the binding of antibody fragments to the light chain of factor VIII.” Thromb Haemost 93, no. 5 (May 2005): 833–41. https://doi.org/10.1160/TH04-11-0729.Full Text Link to Item
-
Lukes, Andrea S., Stephanie Perry, and Thomas L. Ortel. “von Willebrand's disease diagnosed after menorrhagia worsened from levonorgestrel intrauterine system.” Obstet Gynecol 105, no. 5 Pt 2 (May 2005): 1223–26. https://doi.org/10.1097/01.AOG.0000157758.94890.59.Full Text Link to Item
-
James, Andra H., Leo R. Brancazio, and Thomas L. Ortel. “Thrombosis, thrombophilia, and thromboprophylaxis in pregnancy.” Clin Adv Hematol Oncol 3, no. 3 (March 2005): 187–97.Link to Item
-
Lawson, Jeffrey H., Kellie A. Lynn, Reed M. Vanmatre, Taymon Domzalski, Keith F. Klemp, Thomas L. Ortel, Laura E. Niklason, and William Parker. “Antihuman factor V antibodies after use of relatively pure bovine thrombin.” Ann Thorac Surg 79, no. 3 (March 2005): 1037–38. https://doi.org/10.1016/j.athoracsur.2003.09.110.Full Text Link to Item
-
Erkan, Doruk, Thomas L. Ortel, and Michael D. Lockshin. “Warfarin in antiphospholipid syndrome--time to explore new horizons.” J Rheumatol 32, no. 2 (February 2005): 208–12.Link to Item
-
Fassas, Athanasios, Bart Barlogie, James Feusner, Neil E. Kay, and John R. Wingard. “Highlights from the 46 th annual meeting of the American Society of Hematology.” Clin Adv Hematol Oncol 3, no. 2 (February 2005): 111–16.Link to Item
-
Costello, Rebecca, Joan Young, Rebecca Burkholder, Joseph Cranston, Thomas L. Ortel, Steven Dentali, Richard Cotter, Julie O’sullivan Maillet, Bruce Hawkins, and W. Craig Hooper. “Dialogue with patient care organizations.” Thromb Res 117, no. 1–2 (2005): 211–22. https://doi.org/10.1016/j.thromres.2005.07.004.Full Text Link to Item
-
Ortel, Thomas L. “Thrombosis and the antiphospholipid syndrome.” Hematology Am Soc Hematol Educ Program, 2005, 462–68. https://doi.org/10.1182/asheducation-2005.1.462.Full Text Link to Item
-
Ortel, Thomas L. “Clinical implications for patients on antithrombotic therapy while taking supplements.” Thromb Res 117, no. 1–2 (2005): 75–80. https://doi.org/10.1016/j.thromres.2005.04.032.Full Text Link to Item
-
Rand, Jacob H., Xiao-Xuan Wu, Robert Lapinski, Waander L. van Heerde, Chris P. Reutelingsperger, Pojen P. Chen, and Thomas L. Ortel. “Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome.” Blood 104, no. 9 (November 1, 2004): 2783–90. https://doi.org/10.1182/blood-2004-01-0203.Full Text Link to Item
-
Potti, Anil, Christopher P. Rusconi, Bruce A. Sullenger, and Thomas L. Ortel. “Regulatable aptamers in medicine: focus on antithrombotic strategies.” Expert Opin Biol Ther 4, no. 10 (October 2004): 1641–47. https://doi.org/10.1517/14712598.4.10.1641.Full Text Link to Item
-
James, Andra H., Andrea S. Lukes, Leo R. Brancazio, Elizabeth Thames, and Thomas L. Ortel. “Use of a new platelet function analyzer to detect von Willebrand disease in women with menorrhagia.” Am J Obstet Gynecol 191, no. 2 (August 2004): 449–55. https://doi.org/10.1016/j.ajog.2004.03.009.Full Text Link to Item
-
Korompilias, Anastasios V., Thomas L. Ortel, and James R. Urbaniak. “Coagulation abnormalities in patients with hip osteonecrosis.” Orthop Clin North Am 35, no. 3 (July 2004): 265–vii. https://doi.org/10.1016/j.ocl.2004.02.004.Full Text Link to Item
-
Potti, A., B. Danielson, R. Badreddine, and T. Ortel. “Potassium homeostasis in patients receiving prophylactic dose enoxaparin therapy.” J Thromb Haemost 2, no. 7 (July 2004): 1208–9. https://doi.org/10.1111/j.1538-7836.2004.00791.x.Full Text Link to Item
-
Lundblad, Roger L., Ralph A. Bradshaw, Don Gabriel, Thomas L. Ortel, Jeffrey Lawson, and Kenneth G. Mann. “A review of the therapeutic uses of thrombin.” Thromb Haemost 91, no. 5 (May 2004): 851–60. https://doi.org/10.1160/TH03-12-0792.Full Text Link to Item
-
O’shea, Susan I., Jeffrey H. Lawson, Donal Reddan, Michael Murphy, and Thomas L. Ortel. “Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis.” J Vasc Surg 38, no. 3 (September 2003): 541–48. https://doi.org/10.1016/s0741-5214(03)00321-5.Full Text Link to Item
-
Perry, Stephanie L., Susan I. O’Shea, and Thomas L. Ortel. “Management of lepirudin therapy for a patient with antiphospholipid antibody syndrome using the whole blood ecarin clot time and activated partial thromboplastin time.” Blood Coagul Fibrinolysis 14, no. 6 (September 2003): 601–4. https://doi.org/10.1097/00001721-200309000-00014.Full Text Link to Item
-
Su, Zuowei, Tomonori Izumi, and Thomas L. Ortel. “Prothrombin and beta 2-glycoprotein I frequently contribute to antiphospholipid antibody interactions with phospholipids and the generation of abnormal waveform profiles in coagulation assays.” Thromb Haemost 90, no. 2 (August 2003): 218–26. https://doi.org/10.1160/TH02-09-0052.Full Text Link to Item
-
Larned, Zoë L., Susan I. O’Shea, and Thomas L. Ortel. “Heparin-induced thrombocytopenia: clinical presentations and therapeutic management.” Clin Adv Hematol Oncol 1, no. 6 (June 2003): 356–64.Link to Item
-
Lewis, Deborah A., Karen D. Moore, and Thomas L. Ortel. “Binding of factor VIII inhibitors to discrete regions of the factor VIII C2 domain disrupt phospholipid binding.” Blood Coagul Fibrinolysis 14, no. 4 (June 2003): 361–68. https://doi.org/10.1097/00001721-200306000-00007.Full Text Link to Item
-
Carraway, Martha Sue, Karen E. Welty-Wolf, Debra L. Miller, Thomas L. Ortel, Steven Idell, Andrew J. Ghio, Lars C. Petersen, and Claude A. Piantadosi. “Blockade of tissue factor: treatment for organ injury in established sepsis.” Am J Respir Crit Care Med 167, no. 9 (May 1, 2003): 1200–1209. https://doi.org/10.1164/rccm.200204-287OC.Full Text Link to Item
-
Lewis, Deborah A., Mary L. Pound, and Thomas L. Ortel. “Contributions of Asn2198, Met2199, and Phe2200 in the factor VIII C2 domain to cofactor activity, phospholipid-binding, and von Willebrand factor-binding.” Thromb Haemost 89, no. 5 (May 2003): 795–802.Link to Item
-
Perry, Stephanie L., and Thomas L. Ortel. “Clinical and laboratory evaluation of thrombophilia.” Clin Chest Med 24, no. 1 (March 2003): 153–70. https://doi.org/10.1016/s0272-5231(02)00054-0.Full Text Link to Item
-
O’Shea, Susan I., Thomas L. Ortel, and Eugene C. Kovalik. “Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia.” Semin Dial 16, no. 1 (2003): 61–67. https://doi.org/10.1046/j.1525-139x.2003.03014.x.Full Text Link to Item
-
Izumi, T., M. L. Pound, Z. Su, G. M. Iverson, and T. L. Ortel. “Anti-β2-glycoprotein I antibody-mediated inhibition of activated protein C requires binding of β2-glycoprotein I to phospholipids.” Thrombosis and Haemostasis 88, no. 4 (October 1, 2002): 620–26. https://doi.org/10.1055/s-0037-1613265.Full Text
-
Izumi, Tomonori, Mary L. Pound, Zuowei Su, G Michael Iverson, and Thomas L. Ortel. “Anti-beta(2)-glycoprotein I antibody-mediated inhibition of activated protein C requires binding of beta(2)-glycoprotein I to phospholipids.” Thromb Haemost 88, no. 4 (October 2002): 620–26.Link to Item
-
Rusconi, Christopher P., Elizabeth Scardino, Juliana Layzer, George A. Pitoc, Thomas L. Ortel, Dougald Monroe, and Bruce A. Sullenger. “RNA aptamers as reversible antagonists of coagulation factor IXa.” Nature 419, no. 6902 (September 5, 2002): 90–94. https://doi.org/10.1038/nature00963.Full Text Link to Item
-
Moll, Stephan, and Thomas L. Ortel. “Antiphospholipid antibodies.” Arch Intern Med 162, no. 15 (August 12, 2002): 1783–84. https://doi.org/10.1001/archinte.162.15.1783-b.Full Text Link to Item
-
O’Shea, Susan I., and Thomas L. Ortel. “Issues in the utilization of low molecular weight heparins.” Semin Hematol 39, no. 3 (July 2002): 172–78. https://doi.org/10.1053/shem.2002.34090.Full Text Link to Item
-
Welty-Wolf, Karen E., Martha S. Carraway, Thomas L. Ortel, and Claude A. Piantadosi. “Coagulation and inflammation in acute lung injury.” Thromb Haemost 88, no. 1 (July 2002): 17–25.Link to Item
-
Su, Zuowei, Tomonori Izumi, Elizabeth H. Thames, Jeffrey H. Lawson, and Thomas L. Ortel. “Antiphospholipid antibodies after surgical exposure to topical bovine thrombin.” J Lab Clin Med 139, no. 6 (June 2002): 349–56. https://doi.org/10.1067/mlc.2002.123950.Full Text Link to Item
-
Brink, Edward N. van den, Wendy S. Bril, Ellen A. M. Turenhout, Marleen Zuurveld, Niels Bovenschen, Marjolein Peters, Thynn Thynn Yee, et al. “Two classes of germline genes both derived from the V(H)1 family direct the formation of human antibodies that recognize distinct antigenic sites in the C2 domain of factor VIII.” Blood 99, no. 8 (April 15, 2002): 2828–34. https://doi.org/10.1182/blood.v99.8.2828.Full Text Link to Item
-
Izumi, T., M. L. Pound, Z. Su, G. M. Iverson, and T. L. Ortel. “Anti-β2-glycoprotein I antibody-mediated inhibition of activated protein C requires binding of β2-glycoprotein I to phospholipids.” Thrombosis and Haemostasis 88, no. 4 (2002): 620–26.
-
Su, Z., P. J. Braun, K. F. Klemp, K. R. Baker, E. H. Thames, and T. L. Ortel. “Abnormal optical waveform profiles in coagulation assays from patients with antiphospholipid antibodies.” Blood Coagul Fibrinolysis 13, no. 1 (January 2002): 7–17. https://doi.org/10.1097/00001721-200201000-00002.Full Text Link to Item
-
O’Shea, Susan I., Jeffrey J. Sands, Sybil A. Nudo, and Thomas L. Ortel. “Frequency of anti-heparin-platelet factor 4 antibodies in hemodialysis patients and correlation with recurrent vascular access thrombosis.” Am J Hematol 69, no. 1 (January 2002): 72–73. https://doi.org/10.1002/ajh.10032.Full Text Link to Item
-
Yamaguchi, Hiroki, Koiti Inokuchi, Miki Tarusawa, and Kazuo Dan. “Mutation of bcl-x gene in non-Hodgkin's lymphoma.” Am J Hematol 69, no. 1 (January 2002): 74–76. https://doi.org/10.1002/ajh.10030.Full Text Link to Item
-
Welty-Wolf, K. E., M. S. Carraway, D. L. Miller, T. L. Ortel, M. Ezban, A. J. Ghio, S. Idell, and C. A. Piantadosi. “Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons.” Am J Respir Crit Care Med 164, no. 10 Pt 1 (November 15, 2001): 1988–96. https://doi.org/10.1164/ajrccm.164.10.2105027.Full Text Link to Item
-
Schoenecker, J. G., R. K. Johnson, A. P. Lesher, J. D. Day, S. D. Love, M. R. Hoffman, T. L. Ortel, W. Parker, and J. H. Lawson. “Exposure of mice to topical bovine thrombin induces systemic autoimmunity.” Am J Pathol 159, no. 5 (November 2001): 1957–69. https://doi.org/10.1016/S0002-9440(10)63043-X.Full Text Link to Item
-
Welty-Wolf, K. E., M. S. Carraway, S. Idell, T. L. Ortel, M. Ezban, and C. A. Piantadosi. “Tissue factor in experimental acute lung injury.” Semin Hematol 38, no. 4 Suppl 12 (October 2001): 35–38. https://doi.org/10.1053/shem.2001.29505.Full Text Link to Item
-
Hansen, K. E., D. F. Kong, K. D. Moore, and T. L. Ortel. “Risk factors associated with thrombosis in patients with antiphospholipid antibodies.” J Rheumatol 28, no. 9 (September 2001): 2018–24.Link to Item
-
McNeeley, P. A., J. S. Dlott, R. A. Furie, R. M. Jack, T. L. Ortel, D. A. Triplett, E. J. Victoria, and M. D. Linnik. “Beta2-glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of beta2-glycoprotein I.” Thromb Haemost 86, no. 2 (August 2001): 590–95.Link to Item
-
Izumi, T., S. W. Kim, A. Greist, S. Macedo-Ribeiro, P. Fuentes-Prior, W. Bode, W. H. Kane, and T. L. Ortel. “Fine mapping of inhibitory anti-factor V antibodies using factor V C2 domain mutants. Identification of two antigenic epitopes involved in phospholipid binding.” Thromb Haemost 85, no. 6 (June 2001): 1048–54.Link to Item
-
Lewis, D. A., K. D. Moore, and T. L. Ortel. “Factor VIII Arg2304 --> His binds to phosphatidylserine and is a functional cofactor in the factor X-ase complex.” Thromb Haemost 85, no. 2 (February 2001): 260–64.Link to Item
-
Ginsberg, J. A., M. A. Crowther, R. H. White, and T. L. Ortel. “Anticoagulation therapy.” Hematology Am Soc Hematol Educ Program, 2001, 339–57. https://doi.org/10.1182/asheducation-2001.1.339.Full Text Link to Item
-
McNeeley, P. A., J. S. Dlott, R. A. Furie, R. M. Jack, T. L. Ortel, D. A. Triplett, E. J. Victoria, and M. D. Linnik. “β2-Glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of β2-glycoprotein I.” Thrombosis and Haemostasis 86, no. 2 (January 1, 2001): 590–95. https://doi.org/10.1055/s-0037-1616091.Full Text
-
McNeeley, P. A., J. S. Dlott, R. A. Furie, R. M. Jack, T. L. Ortel, D. A. Triplett, E. J. Victoria, and M. D. Linnik. “β2-Glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of β2-glycoprotein I.” Thrombosis and Haemostasis 86, no. 2 (2001): 590–95.
-
Ortel, T. L., M. C. Mercer, E. H. Thames, K. D. Moore, and J. H. Lawson. “Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin.” Ann Surg 233, no. 1 (January 2001): 88–96. https://doi.org/10.1097/00000658-200101000-00014.Full Text Link to Item
-
Welty-Wolf, K. E., M. S. Carraway, S. Idell, T. L. Ortel, M. Ezban, and C. A. Piantadosi. “Tissue factor in experimental acute lung injury.” Seminars in Hematology 38, no. 4 SUPPL. 12 (January 1, 2001): 35–38. https://doi.org/10.1016/s0037-1963(01)90145-3.Full Text
-
Sands, J. J., S. A. Nudo, K. D. Moore, and T. L. Ortel. “Antibodies to prothrombin, factor V, and beta2-glycoprotein I and vascular access thrombosis.” Asaio J 47, no. 5 (2001): 507–10. https://doi.org/10.1097/00002480-200109000-00022.Full Text Link to Item
-
Kelley, M. J., W. Jawien, T. L. Ortel, and J. F. Korczak. “Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly.” Nat Genet 26, no. 1 (September 2000): 106–8. https://doi.org/10.1038/79069.Full Text Link to Item
-
Ortel, T. L., A. H. James, E. H. Thames, K. D. Moore, and C. S. Greenberg. “Assessment of primary hemostasis by PFA-100 analysis in a tertiary care center.” Thromb Haemost 84, no. 1 (July 2000): 93–97.Link to Item
-
Sands, J. J., S. A. Nudo, R. G. Ashford, K. D. Moore, and T. L. Ortel. “Antibodies to topical bovine thrombin correlate with access thrombosis.” Am J Kidney Dis 35, no. 5 (May 2000): 796–801. https://doi.org/10.1016/s0272-6386(00)70247-2.Full Text Link to Item
-
Sands, J. J., S. Nudo, and T. L. Ortel. “Antibodies to prothrombin and factor V correlate-with PTFE graft thrombosis.” Asaio Journal 46, no. 2 (January 1, 2000): 209. https://doi.org/10.1097/00002480-200003000-00233.Full Text
-
Macedo-Ribeiro, S., W. Bode, R. Huber, M. A. Quinn-Allen, S. W. Kim, T. L. Ortel, G. P. Bourenkov, et al. “Crystal structures of the membrane-binding C2 domain of human coagulation factor V.” Nature 402, no. 6760 (November 25, 1999): 434–39. https://doi.org/10.1038/46594.Full Text Link to Item
-
Hansen, K. E., K. D. Moore, T. L. Ortel, and N. B. Allen. “Antiphospholipid antibodies in patients with Wegener's granulomatosis and polyarteritis nodosa.” Arthritis Rheum 42, no. 10 (October 1999): 2250–52. https://doi.org/10.1002/1529-0131(199910)42:10<2250::AID-ANR32>3.0.CO;2-7.Full Text Link to Item
-
Kim, S. W., T. L. Ortel, M. A. Quinn-Allen, L. Yoo, L. Worfolk, X. Zhai, B. R. Lentz, and W. H. Kane. “Partial glycosylation at asparagine-2181 of the second C-type domain of human factor V modulates assembly of the prothrombinase complex.” Biochemistry 38, no. 35 (August 31, 1999): 11448–54. https://doi.org/10.1021/bi991275y.Full Text Link to Item
-
Ortel, T. L. “Clinical and laboratory manifestations of anti-factor V antibodies.” J Lab Clin Med 133, no. 4 (April 1999): 326–34. https://doi.org/10.1016/s0022-2143(99)90062-8.Full Text Link to Item
-
Taylor, C. T., W. P. Petros, and T. L. Ortel. “Two instruments to determine activated partial thromboplastin time: implications for heparin monitoring.” Pharmacotherapy 19, no. 4 (April 1999): 383–87. https://doi.org/10.1592/phco.19.6.383.31039.Full Text Link to Item
-
Goel, N., T. L. Ortel, D. Bali, J. P. Anderson, I. S. Gourley, H. Smith, C. A. Morris, et al. “Familial antiphospholipid antibody syndrome: criteria for disease and evidence for autosomal dominant inheritance.” Arthritis Rheum 42, no. 2 (February 1999): 318–27. https://doi.org/10.1002/1529-0131(199902)42:2<318::AID-ANR15>3.0.CO;2-5.Full Text Link to Item
-
Ortel, T. L., and B. H. Chong. “New treatment options for heparin-induced thrombocytopenia.” Seminars in Hematology 35, no. 4 SUPPL. 5 (December 14, 1998): 26–34.
-
Pechlaner, C., W. Gritsch, and C. Wiedermann. “Diagnosis of pulmonary embolism.” N Engl J Med 339, no. 15 (October 8, 1998): 1084–85.Link to Item
-
Ortel, T. L. “Heparin-induced thrombocytopenia.” Semin Hematol 35, no. 4 Suppl 5 (October 1998): 1–2.Link to Item
-
Ortel, T. L., and B. H. Chong. “New treatment options for heparin-induced thrombocytopenia.” Semin Hematol 35, no. 4 Suppl 5 (October 1998): 26–34.Link to Item
-
Provenzale, J. M., D. P. Frush, and T. L. Ortel. “Recurrent thrombosis of the superior vena cava associated with activated protein C resistance: imaging findings.” Pediatr Radiol 28, no. 8 (August 1998): 597–98. https://doi.org/10.1007/s002470050424.Full Text Link to Item
-
Ortel, T. L., K. D. Moore, M. A. Quinn-Allen, T. Okamura, A. J. Sinclair, J. Lazarchick, R. Govindan, F. Carmagnol, and W. H. Kane. “Inhibitory anti-factor V antibodies bind to the factor V C2 domain and are associated with hemorrhagic manifestations.” Blood 91, no. 11 (June 1, 1998): 4188–96.Link to Item
-
Ortel, T. L., and S. Moll. “Monitoring oral anticoagulant therapy in patients with lupus anticoagulants.” Br J Haematol 101, no. 2 (May 1998): 390–92. https://doi.org/10.1046/j.1365-2141.1998.0738c.x.Full Text Link to Item
-
Provenzale, J. M., D. P. Barboriak, N. B. Allen, and T. L. Ortel. “Antiphospholipid antibodies: findings at arteriography.” Ajnr Am J Neuroradiol 19, no. 4 (April 1998): 611–16.Link to Item
-
Provenzale, J. M., D. P. Barboriak, I. C. Davey, and T. L. Ortel. “Cerebrovascular disease risk factors: neuroradiologic findings in patients with activated protein C resistance.” Radiology 207, no. 1 (April 1998): 85–89. https://doi.org/10.1148/radiology.207.1.9530303.Full Text Link to Item
-
Manoharan, A. “Monitoring warfarin therapy in patients with lupus anticoagulants.” Ann Intern Med 128, no. 6 (March 15, 1998): 504. https://doi.org/10.7326/0003-4819-128-6-199803150-00016.Full Text Link to Item
-
Provenzale, J. M., C. E. Spritzer, R. C. Nelson, and T. L. Ortel. “Disseminated thrombosis in primary antiphospholipid syndrome: MR findings.” Eur J Radiol 26, no. 3 (February 1998): 244–47. https://doi.org/10.1016/s0720-048x(96)01154-0.Full Text Link to Item
-
Provenzale, J. M., D. P. Barboriak, and T. L. Ortel. “Dural sinus thrombosis associated with activated protein C resistance: MR imaging findings and proband identification.” Ajr Am J Roentgenol 170, no. 2 (February 1998): 499–502. https://doi.org/10.2214/ajr.170.2.9456973.Full Text Link to Item
-
Provenzale, J. M., T. L. Ortel, and N. B. Allen. “Systemic thrombosis in patients with antiphospholipid antibodies: lesion distribution and imaging findings.” Ajr Am J Roentgenol 170, no. 2 (February 1998): 285–90. https://doi.org/10.2214/ajr.170.2.9456930.Full Text Link to Item
-
Korompilias, A. V., G. S. Gilkeson, T. L. Ortel, A. V. Seaber, and J. R. Urbaniak. “Anticardiolipin antibodies and osteonecrosis of the femoral head.” Clin Orthop Relat Res, no. 345 (December 1997): 174–80.Link to Item
-
Moll, S., and T. L. Ortel. “Monitoring warfarin therapy in patients with lupus anticoagulants.” Ann Intern Med 127, no. 3 (August 1, 1997): 177–85. https://doi.org/10.7326/0003-4819-127-3-199708010-00001.Full Text Link to Item
-
Hunt, C. M., K. L. Carson, and T. L. Ortel. “Combined factor IX and XI deficiency discovered at liver biopsy.” Dig Dis Sci 42, no. 8 (August 1997): 1731–33. https://doi.org/10.1023/a:1018821701147.Full Text Link to Item
-
Moll, S., M. McCloud, and T. L. Ortel. “Subdural hematoma and lupus anticoagulants.” Stroke 28, no. 3 (March 1997): 646–48. https://doi.org/10.1161/01.str.28.3.646.Full Text Link to Item
-
Layish, D. T., C. E. Spritzer, T. L. Ortel, and V. F. Tapson. “Helical computed tomography and magnetic resonance imaging in the diagnosis of venous thromboembolic disease: Case report and review of the literature.” Clinical Pulmonary Medicine 4, no. 3 (January 1, 1997): 170–73. https://doi.org/10.1097/00045413-199705000-00008.Full Text
-
Lind, S. E., P. W. Callas, E. A. Golden, K. A. Joyner, and T. L. Ortel. “Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic warfarin therapy.” Blood Coagul Fibrinolysis 8, no. 1 (January 1997): 48–53. https://doi.org/10.1097/00001721-199701000-00008.Full Text Link to Item
-
Moll, S., J. D. Igelhart, and T. L. Ortel. “Thrombocytopenia in association with a wandering spleen.” Am J Hematol 53, no. 4 (December 1996): 259–63. https://doi.org/10.1002/(SICI)1096-8652(199612)53:4<259::AID-AJH11>3.0.CO;2-7.Full Text Link to Item
-
Provenzale, J. M., D. P. Barboriak, N. B. Allen, and T. L. Ortel. “Patients with antiphospholipid antibodies: CT and MR findings of the brain.” Ajr Am J Roentgenol 167, no. 6 (December 1996): 1573–78. https://doi.org/10.2214/ajr.167.6.8956600.Full Text Link to Item
-
Ortel, T. L., K. D. Moore, M. Quinn-Allen, and W. H. Kane. “Factor v inhibitors associated with hemorrhagic symptoms bind to a limited region of the factor va light chain.” Journal of Investigative Medicine 44, no. 3 (January 1, 1996).
-
Ortel, T. L., K. D. Moore, M. Ezban, and W. H. Kane. “Effect of heterologous factor V heavy chain sequences on the secretion of recombinant human factor VIII.” Thromb Haemost 75, no. 1 (January 1996): 36–44.Link to Item
-
Provenzale, J. M., T. L. Ortel, and R. C. Nelson. “Adrenal hemorrhage in patients with primary antiphospholipid syndrome: imaging findings.” Ajr Am J Roentgenol 165, no. 2 (August 1995): 361–64. https://doi.org/10.2214/ajr.165.2.7618557.Full Text Link to Item
-
Provenzale, J. M., and T. L. Ortel. “Anatomic distribution of venous thrombosis in patients with antiphospholipid antibody: imaging findings.” Ajr Am J Roentgenol 165, no. 2 (August 1995): 365–68. https://doi.org/10.2214/ajr.165.2.7618558.Full Text Link to Item
-
Macik, B. G., and T. L. Ortel. “Clinical and laboratory evaluation of the hypercoagulable states.” Clin Chest Med 16, no. 2 (June 1995): 375–87.Link to Item
-
Keller, F. G., T. L. Ortel, M. A. Quinn-Allen, and W. H. Kane. “Thrombin-catalyzed activation of recombinant human factor V.” Biochemistry 34, no. 12 (March 28, 1995): 4118–24. https://doi.org/10.1021/bi00012a030.Full Text Link to Item
-
Joyner, K. A., and T. L. Ortel. “A Sensitive DRVVT Reagent System for the Detection of Lupus Anticoagulants.” Clinical and Applied Thrombosis/Hemostasis 1, no. 1 (January 1, 1995): 73–75. https://doi.org/10.1177/107602969500100112.Full Text
-
Greenberg, C. S., M. J. Hursting, B. G. Macik, T. L. Ortel, W. H. Kane, and B. M. Moore. “Evaluation of preanalytical variables associated with measurement of prothrombin fragment 1.2.” Clin Chem 40, no. 10 (October 1994): 1962–69.Link to Item
-
Charles, L. A., D. L. McGlasson, B. A. Hawksworth, J. H. Ashcraft, and T. L. Ortel. “Evaluation of a modified procedure for Staclot LA for the confirmation of lupus anticoagulants.” Blood Coagul Fibrinolysis 5, no. 4 (August 1994): 601–4.Link to Item
-
Provenzale, J. M., E. R. Heinz, T. L. Ortel, B. G. Macik, L. A. Charles, and M. J. Alberts. “Antiphospholipid antibodies in patients without systemic lupus erythematosus: neuroradiologic findings.” Radiology 192, no. 2 (August 1994): 531–37. https://doi.org/10.1148/radiology.192.2.8029427.Full Text Link to Item
-
Ortel, T. L., M. A. Quinn-Allen, F. G. Keller, J. A. Peterson, D. Larocca, and W. H. Kane. “Localization of functionally important epitopes within the second C-type domain of coagulation factor V using recombinant chimeras.” J Biol Chem 269, no. 22 (June 3, 1994): 15898–905.Link to Item
-
Ortel, T. L., L. A. Charles, F. G. Keller, P. K. Marcom, H. N. Oldham, W. H. Kane, and B. G. Macik. “Topical thrombin and acquired coagulation factor inhibitors: clinical spectrum and laboratory diagnosis.” Am J Hematol 45, no. 2 (February 1994): 128–35. https://doi.org/10.1002/ajh.2830450206.Full Text Link to Item
-
Wiedmer, T., S. E. Hall, T. L. Ortel, W. H. Kane, W. F. Rosse, and P. J. Sims. “Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria.” Blood 82, no. 4 (August 15, 1993): 1192–96.Link to Item
-
Ortel, T. L., M. A. Quinn-Allen, L. A. Charles, D. Devore-Carter, and W. H. Kane. “Characterization of an acquired inhibitor to coagulation factor V. Antibody binding to the second C-type domain of factor V inhibits the binding of factor V to phosphatidylserine and neutralizes procoagulant activity.” J Clin Invest 90, no. 6 (December 1992): 2340–47. https://doi.org/10.1172/JCI116123.Full Text Link to Item
-
Ortel, T. L., J. P. Gockerman, R. M. Califf, R. L. McCann, C. M. O’Connor, D. M. Metzler, and C. S. Greenberg. “Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis.” Thromb Haemost 67, no. 3 (March 2, 1992): 292–96.Link to Item
-
Ortel, T. L., D. Devore-Carter, M. Quinn-Allen, and W. H. Kane. “Deletion analysis of recombinant human factor V. Evidence for a phosphatidylserine binding site in the second C-type domain.” J Biol Chem 267, no. 6 (February 25, 1992): 4189–98.Link to Item
-
Doherty, D. C., T. L. Ortel, N. de Bruijn, C. S. Greenberg, and P. Van Trigt. “"Heparin-free" cardiopulmonary bypass: first reported use of heparinoid (Org 10172) to provide anticoagulation for cardiopulmonary bypass.” Anesthesiology 73, no. 3 (September 1990): 562–65.Link to Item
-
Kane, W. H., D. Devore-Carter, and T. L. Ortel. “Expression and characterization of recombinant human factor V and a mutant lacking a major portion of the connecting region.” Biochemistry 29, no. 29 (July 24, 1990): 6762–68. https://doi.org/10.1021/bi00481a003.Full Text Link to Item
-
Ortel, T. L., J. Kallianos, and H. A. Gallis. “Group C streptococcal arthritis: case report and review.” Rev Infect Dis 12, no. 5 (1990): 829–37. https://doi.org/10.1093/clinids/12.5.829.Full Text Link to Item
-
Ozsoylu, S. “High-dose intravenous methylprednisolone for Kasabach-Merritt syndrome.” Am J Hematol 31, no. 3 (July 1989): 219–20. https://doi.org/10.1002/ajh.2830310316.Full Text Link to Item
-
Ortel, T. L. “Author's reply.” American Journal of Hematology 31, no. 3 (January 1, 1989): 220–220. https://doi.org/10.1002/ajh.2830310317.Full Text
-
Ortel, T. L., J. J. Onorato, C. L. Bedrosian, and R. E. Kaufman. “Antifibrinolytic therapy in the management of the Kasabach Merritt syndrome.” Am J Hematol 29, no. 1 (September 1988): 44–48. https://doi.org/10.1002/ajh.2830290111.Full Text Link to Item
-
Ortel, T. L., C. L. Bedrosian, and D. L. Simel. “Arsenic poisoning and seizures.” N C Med J 48, no. 12 (December 1987): 627–30.Link to Item
-
Takahashi, N., Y. Takahashi, T. L. Ortel, J. N. Lozier, N. Ishioka, and F. W. Putnam. “Purification of glycopeptides of human plasma proteins by high-performance liquid chromatography.” J Chromatogr 317 (December 28, 1984): 11–26. https://doi.org/10.1016/s0021-9673(01)91643-7.Full Text Link to Item
-
Ortel, T. L., N. Takahashi, and F. W. Putnam. “Structural model of human ceruloplasmin based on internal triplication, hydrophilic/hydrophobic character, and secondary structure of domains.” Proc Natl Acad Sci U S A 81, no. 15 (August 1984): 4761–65. https://doi.org/10.1073/pnas.81.15.4761.Full Text Link to Item
-
Ortel, T. L., N. Takahashi, and F. W. Putnam. “Structural model of human ceruloplasmin based on internal triplication, hydrophilic/hydrophobic character, and secondary structure of domains.” Proceedings of the National Academy of Sciences of the United States of America 81, no. 15 I (1984): 4761–65.
-
Takahashi, N., T. L. Ortel, and F. W. Putnam. “Single-chain structure of human ceruloplasmin: the complete amino acid sequence of the whole molecule.” Proc Natl Acad Sci U S A 81, no. 2 (January 1984): 390–94. https://doi.org/10.1073/pnas.81.2.390.Full Text Link to Item
-
Ortel, T. L., N. Takahashi, and F. W. Putnam. “Separation of limited tryptic fragments of human ceruloplasmin by gel-permeation high-performance liquid chromatography.” J Chromatogr 266 (August 26, 1983): 257–63. https://doi.org/10.1016/s0021-9673(01)90899-4.Full Text Link to Item
-
Takahashi, N., R. A. Bauman, T. L. Ortel, F. E. Dwulet, C. C. Wang, and F. W. Putnam. “Internal triplication in the structure of human ceruloplasmin.” Proc Natl Acad Sci U S A 80, no. 1 (January 1983): 115–19. https://doi.org/10.1073/pnas.80.1.115.Full Text Link to Item
-
-
Book Sections
-
Daughety, M. M., D. Erkan, M. D. Lockshin, and T. L. Ortel. “Antiphospholipid Syndrome.” In Clinical Immunology: Principles and Practice, Sixth Edition, 788–94, 2022. https://doi.org/10.1016/B978-0-7020-8165-1.00061-7.Full Text
-
Ortel, T. L. “Hematology: Cytopenias.” In Lahita’s Systemic Lupus Erythematosus, 575–82, 2021. https://doi.org/10.1016/B978-0-12-820583-9.00004-X.Full Text
-
Ortel, T. L., D. Erkan, and M. D. Lockshin. “Antiphospholipid Syndrome.” In Clinical Immunology: Principles and Practice, 835-841.e1, 2019. https://doi.org/10.1016/B978-0-7020-6896-6.00061-2.Full Text
-
Ortel, T. L. “Anticoagulation for venous thromboembolism.” In Phlebology, Vein Surgery and Ultrasonography: Diagnosis and Management of Venous Disease, 293–307, 2014. https://doi.org/10.1007/978-3-319-01812-6_21.Full Text
-
Ramiah, V., and T. L. Ortel. “Molecular testing for coagulation abnormalities.” In Molecular Genetic Pathology: Second Edition, 9781461448006:955–74, 2013. https://doi.org/10.1007/978-1-4614-4800-6_36.Full Text
-
Ortel, T. L., P. L. Meroni, M. E. Alarcón-Riquelme, M. O. Borghi, and J. T. Merrill. “What is the genetics of antiphospholipid antibodies/syndrome?” In Antiphospholipid Syndrome: Insights and Highlights from the 13Th International Congress on Antiphospholipid Antibodies, 41–56, 2012. https://doi.org/10.1007/978-1-4614-3194-7_3.Full Text
-
Suwanawiboon, B., and T. L. Ortel. “Anticoagulation in the Perioperative Period.” In Consultative Hemostasis and Thrombosis, 635–46, 2007. https://doi.org/10.1016/B978-141602401-9.10038-0.Full Text
-
-
Conference Papers
-
Refaai, Majed A., Grace Conley, Thomas L. Ortel, and John L. Francis. “Evaluation of a rapid and automated heparin-induced thrombocytopenia immunoassay.” In Int J Lab Hematol, 41:478–84, 2019. https://doi.org/10.1111/ijlh.13029.Full Text Link to Item
-
Khorana, Alok A., Charles W. Francis, Nicole M. Kuderer, Marc Carrier, Thomas L. Ortel, Ted Wun, Deborah Rubens, et al. “Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial.” In Thromb Res, 151:89–95, 2017. https://doi.org/10.1016/j.thromres.2017.01.009.Full Text Link to Item
-
Douketis, J., A. Spyropoulos, S. Kaatz, J. Caprini, A. Dunn, D. Garcia, A. Jacobson, et al. “Bridging anticoagulation in patients who require temporary interruption of warfarin therapy for an elective invasive procedure or surgery (the bridge trial).” In Journal of Thrombosis and Haemostasis, 13:83–84. WILEY-BLACKWELL, 2015.Link to Item
-
-
- Teaching & Mentoring
-
Recent Courses
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.